source: qrda/C0Q/trunk/kids/C0Q-1_SEQ-002_PAT-003.KID@ 1639

Last change on this file since 1639 was 1520, checked in by Sam Habiel, 12 years ago

Changed sequence numbers for patches.

File size: 97.2 KB
Line 
1KIDS Distribution saved on Aug 06, 2012@11:32:48
2QUALITY MEASURES 1.0 PATCH 3
3**KIDS**:C0Q*1.0*3^
4
5**INSTALL NAME**
6C0Q*1.0*3
7"BLD",7936,0)
8C0Q*1.0*3^QUALITY MEASURES^0^3120806^y
9"BLD",7936,1,0)
10^^155^155^3120803^
11"BLD",7936,1,1,0)
12 Summary
13"BLD",7936,1,2,0)
14 =======
15"BLD",7936,1,3,0)
16 This build contains the Quality Measures file (#1130580001.101) fully
17"BLD",7936,1,4,0)
18 populated with the Reminder Rule Sets and if applicable Reminder Extract
19"BLD",7936,1,5,0)
20 definitions for use with the Quality Measures package for reporting for
21"BLD",7936,1,6,0)
22 Meaningful use Stage I.
23"BLD",7936,1,7,0)
24
25"BLD",7936,1,8,0)
26 Source, Copyright, & Licensing:
27"BLD",7936,1,9,0)
28 ===============================
29"BLD",7936,1,10,0)
30 This patch to WorldVistA 2.0 was produced by Sam Habiel on a copy of Dew
31"BLD",7936,1,11,0)
32Drop and tested on a virgin instance of WV EHR 3-09 patched with PXRM 2.0
33"BLD",7936,1,12,0)
34patches 12 and 17. The build was produced in July 2012.
35"BLD",7936,1,13,0)
36 Copyright WorldVistA 2012.
37"BLD",7936,1,14,0)
38 Licensed under GPL version 2 or later. Find it here:
39"BLD",7936,1,15,0)
40http://www.gnu.org/licenses/gpl-2.0.html
41"BLD",7936,1,16,0)
42 Released through VISTA Forum.
43"BLD",7936,1,17,0)
44
45"BLD",7936,1,18,0)
46 Functionality:
47"BLD",7936,1,19,0)
48 ==============
49"BLD",7936,1,20,0)
50 This patch is a pure data patch. It only installs reference data in the
51"BLD",7936,1,21,0)
52C0Q QUALITY MEASURE file (#1130580001.101). It relies on Reminder Package
53"BLD",7936,1,22,0)
54data (specifically rule sets and extracts) sent in C0Q*1.0*2.
55"BLD",7936,1,23,0)
56
57"BLD",7936,1,24,0)
58 Package Elements:
59"BLD",7936,1,25,0)
60 =================
61"BLD",7936,1,26,0)
62 This build transports entries in the C0Q QUALITY MEASURE file.
63"BLD",7936,1,27,0)
64
65"BLD",7936,1,28,0)
66 Routines:
67"BLD",7936,1,29,0)
68 =========
69"BLD",7936,1,30,0)
70 <None>
71"BLD",7936,1,31,0)
72
73"BLD",7936,1,32,0)
74 Documentation:
75"BLD",7936,1,33,0)
76 <None besides this KIDS description>
77"BLD",7936,1,34,0)
78
79"BLD",7936,1,35,0)
80 Test Sites:
81"BLD",7936,1,36,0)
82 ===========
83"BLD",7936,1,37,0)
84 <None>
85"BLD",7936,1,38,0)
86
87"BLD",7936,1,39,0)
88 Compliance:
89"BLD",7936,1,40,0)
90 ===========
91"BLD",7936,1,41,0)
92 This software complies with the VA MUMPS Programming Standards and
93"BLD",7936,1,42,0)
94 Conventions (version 3 April 2007).
95"BLD",7936,1,43,0)
96
97"BLD",7936,1,44,0)
98 Installation Instructions:
99"BLD",7936,1,45,0)
100 ==========================
101"BLD",7936,1,46,0)
102 Pre-installation:
103"BLD",7936,1,47,0)
104
105"BLD",7936,1,48,0)
106 Prerequisite patches: (both found on the trac server here:
107"BLD",7936,1,49,0)
108 https://trac.opensourcevista.net/svn/qrda/C0Q/trunk/kids/)
109"BLD",7936,1,50,0)
110 C0Q*1.0*2
111"BLD",7936,1,51,0)
112 QUALITY MEASURES 1.0
113"BLD",7936,1,52,0)
114
115"BLD",7936,1,53,0)
116 Users can remain on the system while this patch is installed.
117"BLD",7936,1,54,0)
118
119"BLD",7936,1,55,0)
120 Install Time - less than 1 minute.
121"BLD",7936,1,56,0)
122
123"BLD",7936,1,57,0)
124 1. LOAD TRANSPORT GLOBAL
125"BLD",7936,1,58,0)
126
127"BLD",7936,1,59,0)
128 Choose the PackMan message containing this patch and invoke the
129"BLD",7936,1,60,0)
130 INSTALL/CHECK MESSAGE PackMan option to unload the build, or
131"BLD",7936,1,61,0)
132 Use the Load a Distribution option in KIDS to load it from a
133"BLD",7936,1,62,0)
134 host file.
135"BLD",7936,1,63,0)
136
137"BLD",7936,1,64,0)
138 2. START UP KIDS
139"BLD",7936,1,65,0)
140
141"BLD",7936,1,66,0)
142 Start up the Kernel Installation and Distribution System Menu
143"BLD",7936,1,67,0)
144 [XPD MAIN]:
145"BLD",7936,1,68,0)
146
147"BLD",7936,1,69,0)
148 Edits and Distribution ...
149"BLD",7936,1,70,0)
150 Utilities ...
151"BLD",7936,1,71,0)
152 Installation ...
153"BLD",7936,1,72,0)
154
155"BLD",7936,1,73,0)
156 Select Kernel Installation & Distribution System Option: INStallation
157"BLD",7936,1,74,0)
158 ---
159"BLD",7936,1,75,0)
160 Load a Distribution
161"BLD",7936,1,76,0)
162 Print Transport Global
163"BLD",7936,1,77,0)
164 Compare Transport Global to Current System
165"BLD",7936,1,78,0)
166 Verify Checksums in Transport Global
167"BLD",7936,1,79,0)
168 Install Package(s)
169"BLD",7936,1,80,0)
170 Restart Install of Package(s)
171"BLD",7936,1,81,0)
172 Unload a Distribution
173"BLD",7936,1,82,0)
174 Backup a Transport Global
175"BLD",7936,1,83,0)
176
177"BLD",7936,1,84,0)
178 Select Installation Option:
179"BLD",7936,1,85,0)
180
181"BLD",7936,1,86,0)
182 3. Select Installation Option:
183"BLD",7936,1,87,0)
184
185"BLD",7936,1,88,0)
186 NOTE: The following are OPTIONAL - (When prompted for the INSTALL
187"BLD",7936,1,89,0)
188 NAME, enter C0Q*1.0*3):
189"BLD",7936,1,90,0)
190
191"BLD",7936,1,91,0)
192 a. Backup a Transport Global - This option will create a backup
193"BLD",7936,1,92,0)
194 message of any routines exported with this patch. It will not
195"BLD",7936,1,93,0)
196 backup any other changes such as DD's or templates.
197"BLD",7936,1,94,0)
198 b. Compare Transport Global to Current System - This option will
199"BLD",7936,1,95,0)
200 allow you to view all changes that will be made when this patch
201"BLD",7936,1,96,0)
202 is installed. It compares all components of this patch
203"BLD",7936,1,97,0)
204 (routines, DD's, templates, etc.).
205"BLD",7936,1,98,0)
206 c. Verify Checksums in Transport Global - This option will allow
207"BLD",7936,1,99,0)
208 you to ensure the integrity of the routines that are in the
209"BLD",7936,1,100,0)
210 transport global.
211"BLD",7936,1,101,0)
212
213"BLD",7936,1,102,0)
214 4. Select Installation Option: Install Package(s)
215"BLD",7936,1,103,0)
216
217"BLD",7936,1,104,0)
218 **This is the step to start the installation of this KIDS patch:
219"BLD",7936,1,105,0)
220
221"BLD",7936,1,106,0)
222 a. Choose the Install Package(s) option to start the patch install
223"BLD",7936,1,107,0)
224 and enter "C0Q*1.0*3" at the INSTALL NAME prompt.
225"BLD",7936,1,108,0)
226 b. When prompted 'Want KIDS to Rebuild Menu Trees Upon Completion of
227"BLD",7936,1,109,0)
228 Install? NO//' answer NO
229"BLD",7936,1,110,0)
230 c. When prompted 'Want KIDS to INHIBIT LOGONs during the install?
231"BLD",7936,1,111,0)
232 NO//' answer NO
233"BLD",7936,1,112,0)
234 d. When prompted 'Want to DISABLE Scheduled Options, Menu Options,
235"BLD",7936,1,113,0)
236 and Protocols? NO//' answer NO
237"BLD",7936,1,114,0)
238
239"BLD",7936,1,115,0)
240
241"BLD",7936,1,116,0)
242Here is an example installation log.
243"BLD",7936,1,117,0)
244Select INSTALL NAME: C0Q*1.0*3 Loaded from Distribution Loaded
245"BLD",7936,1,118,0)
246from Di
247"BLD",7936,1,119,0)
248stribution 8/3/12@16:32:30
249"BLD",7936,1,120,0)
250 => SDFGHJKL ;Created on Aug 03, 2012@16:31:28
251"BLD",7936,1,121,0)
252
253"BLD",7936,1,122,0)
254This Distribution was loaded on Aug 03, 2012@16:32:30 with header of
255"BLD",7936,1,123,0)
256 SDFGHJKL ;Created on Aug 03, 2012@16:31:28
257"BLD",7936,1,124,0)
258 It consisted of the following Install(s):
259"BLD",7936,1,125,0)
260 C0Q*1.0*3
261"BLD",7936,1,126,0)
262
263"BLD",7936,1,127,0)
264 Checking C0Q*1.0*3 for overlap with VOE 1.0 . OK
265"BLD",7936,1,128,0)
266 No overlap found
267"BLD",7936,1,129,0)
268DEVICE: HOME// PHOME HOME PRINTER
269"BLD",7936,1,130,0)
270
271"BLD",7936,1,131,0)
272
273"BLD",7936,1,132,0)
274 Install Started for C0Q*1.0*3 :
275"BLD",7936,1,133,0)
276 Aug 03, 2012@16:35:24
277"BLD",7936,1,134,0)
278
279"BLD",7936,1,135,0)
280Build Distribution Date: Aug 03, 2012
281"BLD",7936,1,136,0)
282
283"BLD",7936,1,137,0)
284 Installing Routines:.
285"BLD",7936,1,138,0)
286 Aug 03, 2012@16:35:24
287"BLD",7936,1,139,0)
288
289"BLD",7936,1,140,0)
290 Installing Data Dictionaries: ..
291"BLD",7936,1,141,0)
292 Aug 03, 2012@16:35:24
293"BLD",7936,1,142,0)
294
295"BLD",7936,1,143,0)
296 Installing Data:
297"BLD",7936,1,144,0)
298 Aug 03, 2012@16:35:24
299"BLD",7936,1,145,0)
300
301"BLD",7936,1,146,0)
302 Updating Routine file.....
303"BLD",7936,1,147,0)
304
305"BLD",7936,1,148,0)
306 Updating KIDS files.......
307"BLD",7936,1,149,0)
308
309"BLD",7936,1,150,0)
310 C0Q*1.0*3 Installed.
311"BLD",7936,1,151,0)
312 Aug 03, 2012@16:35:24
313"BLD",7936,1,152,0)
314
315"BLD",7936,1,153,0)
316 Not a VA primary domain
317"BLD",7936,1,154,0)
318
319"BLD",7936,1,155,0)
320 NO Install Message sent
321"BLD",7936,4,0)
322^9.64PA^1130580001.101^1
323"BLD",7936,4,1130580001.101,0)
3241130580001.101
325"BLD",7936,4,1130580001.101,222)
326y^y^f^^y^^y^o^n
327"BLD",7936,4,"B",1130580001.101,1130580001.101)
328
329"BLD",7936,6.3)
33012
331"BLD",7936,"ABPKG")
332n
333"BLD",7936,"KRN",0)
334^9.67PA^779.2^20
335"BLD",7936,"KRN",.4,0)
336.4
337"BLD",7936,"KRN",.401,0)
338.401
339"BLD",7936,"KRN",.402,0)
340.402
341"BLD",7936,"KRN",.403,0)
342.403
343"BLD",7936,"KRN",.5,0)
344.5
345"BLD",7936,"KRN",.84,0)
346.84
347"BLD",7936,"KRN",3.6,0)
3483.6
349"BLD",7936,"KRN",3.8,0)
3503.8
351"BLD",7936,"KRN",9.2,0)
3529.2
353"BLD",7936,"KRN",9.8,0)
3549.8
355"BLD",7936,"KRN",19,0)
35619
357"BLD",7936,"KRN",19.1,0)
35819.1
359"BLD",7936,"KRN",101,0)
360101
361"BLD",7936,"KRN",409.61,0)
362409.61
363"BLD",7936,"KRN",771,0)
364771
365"BLD",7936,"KRN",779.2,0)
366779.2
367"BLD",7936,"KRN",870,0)
368870
369"BLD",7936,"KRN",8989.51,0)
3708989.51
371"BLD",7936,"KRN",8989.52,0)
3728989.52
373"BLD",7936,"KRN",8994,0)
3748994
375"BLD",7936,"KRN","B",.4,.4)
376
377"BLD",7936,"KRN","B",.401,.401)
378
379"BLD",7936,"KRN","B",.402,.402)
380
381"BLD",7936,"KRN","B",.403,.403)
382
383"BLD",7936,"KRN","B",.5,.5)
384
385"BLD",7936,"KRN","B",.84,.84)
386
387"BLD",7936,"KRN","B",3.6,3.6)
388
389"BLD",7936,"KRN","B",3.8,3.8)
390
391"BLD",7936,"KRN","B",9.2,9.2)
392
393"BLD",7936,"KRN","B",9.8,9.8)
394
395"BLD",7936,"KRN","B",19,19)
396
397"BLD",7936,"KRN","B",19.1,19.1)
398
399"BLD",7936,"KRN","B",101,101)
400
401"BLD",7936,"KRN","B",409.61,409.61)
402
403"BLD",7936,"KRN","B",771,771)
404
405"BLD",7936,"KRN","B",779.2,779.2)
406
407"BLD",7936,"KRN","B",870,870)
408
409"BLD",7936,"KRN","B",8989.51,8989.51)
410
411"BLD",7936,"KRN","B",8989.52,8989.52)
412
413"BLD",7936,"KRN","B",8994,8994)
414
415"BLD",7936,"QUES",0)
416^9.62^^
417"BLD",7936,"REQB",0)
418^9.611^2^2
419"BLD",7936,"REQB",1,0)
420C0Q*1.0*2^2
421"BLD",7936,"REQB",2,0)
422QUALITY MEASURES 1.0^2
423"BLD",7936,"REQB","B","C0Q*1.0*2",1)
424
425"BLD",7936,"REQB","B","QUALITY MEASURES 1.0",2)
426
427"DATA",1130580001.101,4,0)
428PQRI MEASURE 124^^^2.16.840.1.113883.3.249.11.11
429"DATA",1130580001.101,4,1)
430Measure #124: Health Information Technology (HIT): Adoption/Use of Electronic Health Records
431"DATA",1130580001.101,4,4)
432PQRI-124
433"DATA",1130580001.101,4,5)
434Adoption/Use of Electronic Health Records (EHR)
435"DATA",1130580001.101,4,6,0)
436^^3^3^3101013^
437"DATA",1130580001.101,4,6,1,0)
438Documents whether provider has adopted and is using health inf
439"DATA",1130580001.101,4,6,2,0)
440ormation technology. To qualify, the provider must havea adopted and be
441"DATA",1130580001.101,4,6,3,0)
442using a certified/qualified electronic health record (EHR)
443"DATA",1130580001.101,6,0)
444PQRI MEASURE 47^^^2.16.840.1.113883.3.249.11.52
445"DATA",1130580001.101,6,1)
446Measure #47: Advance Care Plan
447"DATA",1130580001.101,6,4)
448PQRI-47
449"DATA",1130580001.101,6,5)
450Advance Care Plan
451"DATA",1130580001.101,6,6,0)
452^1130580001.111^5^5^3101014^^^
453"DATA",1130580001.101,6,6,1,0)
454Percentage of patients age 65 and older who have an advanced care plan or
455"DATA",1130580001.101,6,6,2,0)
456surrogate decision maker documented in the medical record or documented
457"DATA",1130580001.101,6,6,3,0)
458in the medical record that an advance care plan was discussed but the
459"DATA",1130580001.101,6,6,4,0)
460patient did not wish or was not able to name a surrogate decision maker
461"DATA",1130580001.101,6,6,5,0)
462or provide an advance care plan.
463"DATA",1130580001.101,7,0)
464PQRI MEASURE 48^^^2.16.840.1.113883.3.249.11.53
465"DATA",1130580001.101,7,1)
466Measure #48: Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older
467"DATA",1130580001.101,7,4)
468PQRI-48
469"DATA",1130580001.101,7,5)
470Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older
471"DATA",1130580001.101,7,6,0)
472^^3^3^3101013^
473"DATA",1130580001.101,7,6,1,0)
474Percentage of patients equal to or older than 65 years of age at the
475"DATA",1130580001.101,7,6,2,0)
476beginning of the measurement perion who were assesed for the presence or
477"DATA",1130580001.101,7,6,3,0)
478absence of urinary incontinence within 12 months
479"DATA",1130580001.101,12,0)
480MU EP NQF 0043^^^2.16.840.1.113883.3.249.11.8
481"DATA",1130580001.101,12,1)
482Measure #111: Preventive Care and Screening: Pneumonia Vaccination for Patients 65 Years and Older
483"DATA",1130580001.101,12,4)
484PQRI-111
485"DATA",1130580001.101,12,5)
486Pneumonia Vaccination for Patients 65 Years and Older
487"DATA",1130580001.101,12,6,0)
488^1130580001.111^2^2^3120730^^
489"DATA",1130580001.101,12,6,1,0)
490Percentage of patients afed 65 years and older who have ever r
491"DATA",1130580001.101,12,6,2,0)
492eceived a pneumoccal vaccine
493"DATA",1130580001.101,12,7)
494NQF0043
495"DATA",1130580001.101,14,0)
496PQRI MEASURE 39^^^2.16.840.1.113883.3.249.11.51
497"DATA",1130580001.101,14,1)
498Measure #39: Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older
499"DATA",1130580001.101,14,4)
500PQRI-39
501"DATA",1130580001.101,14,5)
502Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older
503"DATA",1130580001.101,14,6,0)
504^^3^3^3101013^
505"DATA",1130580001.101,14,6,1,0)
506Percentage of patients who had a DXA measurement ordered or pe
507"DATA",1130580001.101,14,6,2,0)
508rformed at least once since age 60 or pharmacologic therapy prescribed
509"DATA",1130580001.101,14,6,3,0)
510within 12 months before the end of the measurement period
511"DATA",1130580001.101,16,0)
512PQRI MEASURE 173^^^2.16.840.1.113883.3.249.11.55
513"DATA",1130580001.101,16,1)
514Measure #173: Preventive Care and Screening: Unhealthy Alcohol Use - Screening
515"DATA",1130580001.101,16,4)
516PQRI-173
517"DATA",1130580001.101,16,5)
518Preventive Care and Screening: Unhealthy Alcohol Use - Screening
519"DATA",1130580001.101,16,6,0)
520^^2^2^3101013^
521"DATA",1130580001.101,16,6,1,0)
522Percentage of patients aged 18 years and older who were screen
523"DATA",1130580001.101,16,6,2,0)
524ed for unhealthy alcohol use using a systematic method within 24 months
525"DATA",1130580001.101,23,0)
526MU HOS NQF 0495
527"DATA",1130580001.101,23,1)
528ED THROUGHPUT ARRIVAL TO DEPARTURE
529"DATA",1130580001.101,23,5)
530ED THROUGHPUT ARRIVAL TO DEPARTURE
531"DATA",1130580001.101,23,6,0)
532^1130580001.111^3^3^3110430^^^^
533"DATA",1130580001.101,23,6,1,0)
534Median time from emergency department arrival to time of departure from
535"DATA",1130580001.101,23,6,2,0)
536the emergency room for patients admitted to the facility from the
537"DATA",1130580001.101,23,6,3,0)
538emergency department
539"DATA",1130580001.101,23,7)
540NQF0495^^^^^^88^165
541"DATA",1130580001.101,24,0)
542MU HOS NQF 0497
543"DATA",1130580001.101,24,1)
544ED THROUGHPUT ADMITTING DECISION TO DEPARTURE
545"DATA",1130580001.101,24,5)
546ED THROUGHPUT ADMITTING DECISION TO DEPARTURE
547"DATA",1130580001.101,24,6,0)
548^^3^3^3110430^
549"DATA",1130580001.101,24,6,1,0)
550Median time from admit decision time to time of departure from the
551"DATA",1130580001.101,24,6,2,0)
552emergency department of emergency department patients admitted to
553"DATA",1130580001.101,24,6,3,0)
554inpatient status
555"DATA",1130580001.101,24,7)
556NQF0497^^^^^^90^168
557"DATA",1130580001.101,25,0)
558MU HOS NQF 0435
559"DATA",1130580001.101,25,1)
560Ischemic stroke.Discharge on anti-thrombotics
561"DATA",1130580001.101,25,5)
562 Ischemic stroke.Discharge on anti-thrombotic
563"DATA",1130580001.101,25,6,0)
564^^2^2^3110430^
565"DATA",1130580001.101,25,6,1,0)
566Ischemic stroke patients prescribed antithrombotic therapy at hospital
567"DATA",1130580001.101,25,6,2,0)
568discharge
569"DATA",1130580001.101,25,7)
570NQF0435^^^^^^114^115
571"DATA",1130580001.101,26,0)
572MU HOS NQF 0436
573"DATA",1130580001.101,26,1)
574 Ischemic stroke.Anticoagulation for A-fib/flutter
575"DATA",1130580001.101,26,5)
576Ischemic stroke.Anticoagulation for A-fib/flutter
577"DATA",1130580001.101,26,6,0)
578^1130580001.111^2^2^3110430^^^
579"DATA",1130580001.101,26,6,1,0)
580 Ischemic stroke patients with atrial fibrillation/flutter who are
581"DATA",1130580001.101,26,6,2,0)
582prescribed anticoagulation therapy at hospital discharge
583"DATA",1130580001.101,26,7)
584NQF0436^^^^^^116^117
585"DATA",1130580001.101,27,0)
586MU HOS NQF 0437
587"DATA",1130580001.101,27,1)
588 Ischemic stroke.Thrombolytic therapy for patients arriving within 2 hours of symptom onset
589"DATA",1130580001.101,27,5)
590Ischemic stroke.Thrombolytic therapy for patients arriving within 2 hours of symptom onset
591"DATA",1130580001.101,27,6,0)
592^^3^3^3110430^
593"DATA",1130580001.101,27,6,1,0)
594Acute ischemic stroke patients who arrive at this hospital within 2
595"DATA",1130580001.101,27,6,2,0)
596hours of time last known well and for whom IV t-PA was initiated at this
597"DATA",1130580001.101,27,6,3,0)
598hospital within 3 hours of time last known well.
599"DATA",1130580001.101,27,7)
600NQF0437^^^^^^119^118
601"DATA",1130580001.101,28,0)
602MU HOS NQF 0438
603"DATA",1130580001.101,28,1)
604Ischemic or hemorrhagic stroke.Antithrombotic therapy by day 2
605"DATA",1130580001.101,28,5)
606Ischemic or hemorrhagic stroke.Antithrombotic therapy by day 2
607"DATA",1130580001.101,28,6,0)
608^^2^2^3110430^
609"DATA",1130580001.101,28,6,1,0)
610Ischemic stroke patients administered antithrombotic therapy by the
611"DATA",1130580001.101,28,6,2,0)
612end of hospital day 2.
613"DATA",1130580001.101,28,7)
614NQF0438^^^^^^120^121
615"DATA",1130580001.101,29,0)
616MU HOS NQF 0439
617"DATA",1130580001.101,29,1)
618Ischemic stroke.Discharge on statins
619"DATA",1130580001.101,29,5)
620Ischemic stroke.Discharge on statins
621"DATA",1130580001.101,29,6,0)
622^^3^3^3110430^
623"DATA",1130580001.101,29,6,1,0)
624Ischemic stroke patients with LDL > 100 mg/dL, or LDL not measured, or,
625"DATA",1130580001.101,29,6,2,0)
626who were on a lipid-lowering medication prior to hospital arrival are
627"DATA",1130580001.101,29,6,3,0)
628prescribed statin medication at hospital discharge
629"DATA",1130580001.101,29,7)
630NQF0439^^^^^^122^123
631"DATA",1130580001.101,30,0)
632MU HOS NQF 0440
633"DATA",1130580001.101,30,1)
634Ischemic or hemorrhagic stroke.Stroke education
635"DATA",1130580001.101,30,5)
636Ischemic or hemorrhagic stroke.Stroke education
637"DATA",1130580001.101,30,6,0)
638^^5^5^3110430^
639"DATA",1130580001.101,30,6,1,0)
640Ischemic or hemorrhagic stroke patients or their caregivers who were
641"DATA",1130580001.101,30,6,2,0)
642given educational materials during the hospital stay addressing all of the
643"DATA",1130580001.101,30,6,3,0)
644following: activation of emergency medical system, need for follow-up
645"DATA",1130580001.101,30,6,4,0)
646after discharge, medications prescribed at discharge, risk factors for
647"DATA",1130580001.101,30,6,5,0)
648stroke, and warning signs and symptoms of stroke.
649"DATA",1130580001.101,30,7)
650NQF0440^^^^^^124^125
651"DATA",1130580001.101,31,0)
652MU HOS NQF 0441
653"DATA",1130580001.101,31,1)
654Ischemic or hemorrhagic stroke.Rehabilitation assessment
655"DATA",1130580001.101,31,5)
656Ischemic or hemorrhagic stroke.Rehabilitation assessment
657"DATA",1130580001.101,31,6,0)
658^^2^2^3110430^
659"DATA",1130580001.101,31,6,1,0)
660Ischemic or hemorrhagic stroke patients who were assessed for
661"DATA",1130580001.101,31,6,2,0)
662rehabilitation services.
663"DATA",1130580001.101,31,7)
664NQF0441^^^^^^126^127
665"DATA",1130580001.101,32,0)
666MU HOS NQF 0371
667"DATA",1130580001.101,32,1)
668VTE prophylaxis within 24 hours of arrival
669"DATA",1130580001.101,32,5)
670VTE prophylaxis within 24 hours of arrival
671"DATA",1130580001.101,32,6,0)
672^^4^4^3110430^
673"DATA",1130580001.101,32,6,1,0)
674This measure assesses the number of patients who received VTE prophylaxis
675"DATA",1130580001.101,32,6,2,0)
676or have documentation why no VTE prophylaxis was given the day of or the
677"DATA",1130580001.101,32,6,3,0)
678day after hospital admission or surgery end date for surgeries that start
679"DATA",1130580001.101,32,6,4,0)
680the day of or the day after hospital admission.
681"DATA",1130580001.101,32,7)
682NQF0371^^^^^^69^67
683"DATA",1130580001.101,33,0)
684MU HOS NQF 0372
685"DATA",1130580001.101,33,1)
686ICU VTE prophylaxis
687"DATA",1130580001.101,33,5)
688ICU VTE prophylaxis
689"DATA",1130580001.101,33,6,0)
690^^5^5^3110430^
691"DATA",1130580001.101,33,6,1,0)
692This measure assesses the number of patients who received VTE prophylaxis
693"DATA",1130580001.101,33,6,2,0)
694or have documentation why no VTE prophylaxis was given the day of or the
695"DATA",1130580001.101,33,6,3,0)
696day after the initial admission (or transfer) to the Intensive Care Unit
697"DATA",1130580001.101,33,6,4,0)
698(ICU) or surgery end date for surgeries that start the day of or the day
699"DATA",1130580001.101,33,6,5,0)
700after ICU admission (or transfer).
701"DATA",1130580001.101,33,7)
702NQF0372^^^^^^128^71
703"DATA",1130580001.101,34,0)
704MU HOS NQF 0373
705"DATA",1130580001.101,34,1)
706Anticoagulation overlap therapy
707"DATA",1130580001.101,34,5)
708Anticoagulation overlap therapy
709"DATA",1130580001.101,34,6,0)
710^^8^8^3110430^
711"DATA",1130580001.101,34,6,1,0)
712This measure assesses the number of patients diagnosed with confirmed VTE
713"DATA",1130580001.101,34,6,2,0)
714who received an overlap of parenteral (intravenous [IV] or subcutaneous
715"DATA",1130580001.101,34,6,3,0)
716[subcu]) anticoagulation and warfarin therapy. For patients who received
717"DATA",1130580001.101,34,6,4,0)
718less than five days of overlap therapy, they must be discharged on both
719"DATA",1130580001.101,34,6,5,0)
720medications. Overlap therapy must be administered for at least five days
721"DATA",1130580001.101,34,6,6,0)
722with an international normalized ratio (INR) . 2 prior to discontinuation
723"DATA",1130580001.101,34,6,7,0)
724of the parenteral anticoagulation therapy or the patient must be
725"DATA",1130580001.101,34,6,8,0)
726discharged on both medications.
727"DATA",1130580001.101,34,7)
728NQF0373^^^^^^129^144
729"DATA",1130580001.101,35,0)
730MU HOS NQF 0374
731"DATA",1130580001.101,35,1)
732Platelet monitoring on unfractionated heparin
733"DATA",1130580001.101,35,5)
734Platelet monitoring on unfractionated heparin
735"DATA",1130580001.101,35,6,0)
736^^10^10^3110430^
737"DATA",1130580001.101,35,6,1,0)
738This measure assesses the number of patients diagnosed with confirmed VTE
739"DATA",1130580001.101,35,6,2,0)
740who received intravenous (IV) UFH therapy dosages AND had their platelet
741"DATA",1130580001.101,35,6,3,0)
742counts monitored using defined parameters such as a nomogram or
743"DATA",1130580001.101,35,6,4,0)
744protocol This measure assesses the number of patients diagnosed with
745"DATA",1130580001.101,35,6,5,0)
746confirmed VTE who received intravenous (IV) UFH therapy dosages AND had
747"DATA",1130580001.101,35,6,6,0)
748their platelet counts monitored using defined parameters such as a
749"DATA",1130580001.101,35,6,7,0)
750nomogram or protocol This measure assesses the number of patients
751"DATA",1130580001.101,35,6,8,0)
752diagnosed with confirmed VTE who received intravenous (IV) UFH therapy
753"DATA",1130580001.101,35,6,9,0)
754dosages AND had their platelet counts monitored using defined parameters
755"DATA",1130580001.101,35,6,10,0)
756such as a nomogram or protocol
757"DATA",1130580001.101,35,7)
758NQF0374^^^^^^145^146
759"DATA",1130580001.101,36,0)
760MU HOS NQF 0375
761"DATA",1130580001.101,36,1)
762VTE discharge instructions
763"DATA",1130580001.101,36,5)
764VTE discharge instructions
765"DATA",1130580001.101,36,6,0)
766^^11^11^3110430^
767"DATA",1130580001.101,36,6,1,0)
768This measure assesses the number of patients diagnosed with confirmed VTE
769"DATA",1130580001.101,36,6,2,0)
770that are discharged to home, to home with home health, home hospice or
771"DATA",1130580001.101,36,6,3,0)
772discharged/transferred to court/law enforcement on warfarin with written
773"DATA",1130580001.101,36,6,4,0)
774discharge instructions that address all four criteria: compliance issues,
775"DATA",1130580001.101,36,6,5,0)
776dietary advice, follow-up This measure assesses the number of patients
777"DATA",1130580001.101,36,6,6,0)
778diagnosed with confirmed VTE that are discharged to home, to home with
779"DATA",1130580001.101,36,6,7,0)
780home health, home hospice or discharged/transferred to court/law
781"DATA",1130580001.101,36,6,8,0)
782enforcement on warfarin with written discharge instructions that address
783"DATA",1130580001.101,36,6,9,0)
784all four criteria: compliance issues, dietary advice, follow-up
785"DATA",1130580001.101,36,6,10,0)
786monitoring, and information about the potential for adverse drug
787"DATA",1130580001.101,36,6,11,0)
788reactions/interactions.
789"DATA",1130580001.101,36,7)
790NQF0375^^^^^^147^156
791"DATA",1130580001.101,37,0)
792MU HOS NQF 0376
793"DATA",1130580001.101,37,1)
794Incidence of potentially preventable VTE
795"DATA",1130580001.101,37,5)
796Incidence of potentially preventable VTE
797"DATA",1130580001.101,37,6,0)
798^^4^4^3110430^
799"DATA",1130580001.101,37,6,1,0)
800This measure assesses the number of patients diagnosed with confirmed VTE
801"DATA",1130580001.101,37,6,2,0)
802during hospitalization (not present on arrival) who did not receive VTE
803"DATA",1130580001.101,37,6,3,0)
804prophylaxis between hospital admission and the day before the VTE
805"DATA",1130580001.101,37,6,4,0)
806diagnostic testing order date.
807"DATA",1130580001.101,37,7)
808NQF0376^^^^^^158^162
809"DATA",1130580001.101,39,0)
810MU EP NQF 0421^^^2.16.840.1.113883.3.249.11.54
811"DATA",1130580001.101,39,1)
812NQF0421 Adult Weight Screening and Follow-Up
813"DATA",1130580001.101,39,4)
814PQRI-128
815"DATA",1130580001.101,39,5)
816NQF0421 Adult Weight Screening and Follow-Up
817"DATA",1130580001.101,39,6,0)
818^1130580001.111^6^6^3110628^^^^
819"DATA",1130580001.101,39,6,1,0)
820Percentage of patients aged 18
821"DATA",1130580001.101,39,6,2,0)
822years and older with a calculated BMI in the past
823"DATA",1130580001.101,39,6,3,0)
824six months or during the current visit documented in
825"DATA",1130580001.101,39,6,4,0)
826the medical record AND if the most recent BMI is
827"DATA",1130580001.101,39,6,5,0)
828outside parameters, a follow-up plan is
829"DATA",1130580001.101,39,6,6,0)
830documented.
831"DATA",1130580001.101,39,7)
832NQF0421^^^^^^321^320^10
833"DATA",1130580001.101,40,0)
834MU EP NQF 0013^^^2.16.840.1.113883.3.249.11.56
835"DATA",1130580001.101,40,1)
836NQF0013 Hypertension: Blood Pressure Measurement
837"DATA",1130580001.101,40,4)
838PQRI-13
839"DATA",1130580001.101,40,5)
840NQF0013 Hypertension: Blood Pressure Measurement
841"DATA",1130580001.101,40,6,0)
842^1130580001.111^4^4^3110628^^
843"DATA",1130580001.101,40,6,1,0)
844Percentage of patient visits for patients
845"DATA",1130580001.101,40,6,2,0)
846aged 18 years and older with a diagnosis of hypertension
847"DATA",1130580001.101,40,6,3,0)
848who have been seen for at least 2 office visits, with blood
849"DATA",1130580001.101,40,6,4,0)
850pressure (BP) recorded
851"DATA",1130580001.101,40,7)
852NQF0013^^^^^^142^167
853"DATA",1130580001.101,41,0)
854MU EP NQF 0028A^^^2.16.840.1.113883.3.249.11.59
855"DATA",1130580001.101,41,1)
856NQF0028A Preventive Care and Screening Measure Pair: a. Tobacco Use Assessment,b. Tobacco Cessation Intervention
857"DATA",1130580001.101,41,4)
858PQRI-28
859"DATA",1130580001.101,41,5)
860NQF0028A Tobacco Use Assessment
861"DATA",1130580001.101,41,6,0)
862^1130580001.111^7^7^3110625^^^
863"DATA",1130580001.101,41,6,1,0)
864 Percentage of patients aged 18 years and
865"DATA",1130580001.101,41,6,2,0)
866older who have been seen for at least 2 office visits who
867"DATA",1130580001.101,41,6,3,0)
868were queried about tobacco use one or more times within
869"DATA",1130580001.101,41,6,4,0)
87024 months b. Percentage of patients aged 18 years and
871"DATA",1130580001.101,41,6,5,0)
872older identified as tobacco users within the past 24
873"DATA",1130580001.101,41,6,6,0)
874months and have been seen for at least 2 office visits,
875"DATA",1130580001.101,41,6,7,0)
876who received cessation intervention.
877"DATA",1130580001.101,41,7)
878NQF0028A^^^^^^157^160
879"DATA",1130580001.101,42,0)
880MU EP NQF 0041^^^2.16.840.1.113883.3.249.11.7
881"DATA",1130580001.101,42,1)
882Preventive Care and Screening: Influenza Immunization for Patients >= 50 Years Old
883"DATA",1130580001.101,42,4)
884PQRI-110
885"DATA",1130580001.101,42,5)
886NQF0041 Influenza Immunization 50 years and older
887"DATA",1130580001.101,42,6,0)
888^^4^4^3110430^
889"DATA",1130580001.101,42,6,1,0)
890Percentage of patients aged 50 years
891"DATA",1130580001.101,42,6,2,0)
892and older who received an influenza immunization
893"DATA",1130580001.101,42,6,3,0)
894during the flu season (September through
895"DATA",1130580001.101,42,6,4,0)
896February).
897"DATA",1130580001.101,42,7)
898NQF0041^^^^^^242^243
899"DATA",1130580001.101,43,0)
900MU EP NQF 0024
901"DATA",1130580001.101,43,1)
902NQF0024 Weight Assessment and Counseling for Children and Adolescents (ALL)
903"DATA",1130580001.101,43,5)
904NQF0024 Weight Assessment and Counseling for Children and Adolescents (ALL)
905"DATA",1130580001.101,43,6,0)
906^^6^6^3120803^
907"DATA",1130580001.101,43,6,1,0)
908Percentage of patients 2 -17 years of age
909"DATA",1130580001.101,43,6,2,0)
910who had an outpatient visit with a Primary Care Physician
911"DATA",1130580001.101,43,6,3,0)
912(PCP) or OB/GYN and who had evidence of BMI
913"DATA",1130580001.101,43,6,4,0)
914percentile documentation, counseling for nutrition and
915"DATA",1130580001.101,43,6,5,0)
916counseling for physical activity during the measurement
917"DATA",1130580001.101,43,6,6,0)
918year. This specific Quality Measure is for all the children.
919"DATA",1130580001.101,43,7)
920NQF0024 ALL^^^^^^151^149
921"DATA",1130580001.101,44,0)
922MU EP NQF 0038^^^2.16.840.1.113883.3.249.11.60
923"DATA",1130580001.101,44,1)
924Childhood Immunization Status
925"DATA",1130580001.101,44,4)
926PQRI-38
927"DATA",1130580001.101,44,5)
928Childhood Immunization Status
929"DATA",1130580001.101,44,6,0)
930^^14^14^3110430^
931"DATA",1130580001.101,44,6,1,0)
932Percentage of children 2 years of age who
933"DATA",1130580001.101,44,6,2,0)
934had four diphtheria, tetanus and acellular pertussis
935"DATA",1130580001.101,44,6,3,0)
936(DTaP); three polio(IPV), one measles, ,mumps and
937"DATA",1130580001.101,44,6,4,0)
938rubella (MMR); two H influenza type B (HiB); three
939"DATA",1130580001.101,44,6,5,0)
940Percentage of children 2 years of age who
941"DATA",1130580001.101,44,6,6,0)
942had four diphtheria, tetanus and acellular pertussis
943"DATA",1130580001.101,44,6,7,0)
944(DTaP); three polio(IPV), one measles, ,mumps and
945"DATA",1130580001.101,44,6,8,0)
946rubella (MMR); two H influenza type B (HiB); three
947"DATA",1130580001.101,44,6,9,0)
948hepatitis B (Hep B); one chicken pox (VZV); four
949"DATA",1130580001.101,44,6,10,0)
950pneumococcal conjugate (PCV); two hepatitis A (Hep A);
951"DATA",1130580001.101,44,6,11,0)
952two or three rotavirus (RV); and two influenza (flu)
953"DATA",1130580001.101,44,6,12,0)
954vaccines by their second birthday. The measure
955"DATA",1130580001.101,44,6,13,0)
956calculates a rate for each vaccine and nine separate
957"DATA",1130580001.101,44,6,14,0)
958combination rates.
959"DATA",1130580001.101,44,7)
960NQF0038
961"DATA",1130580001.101,45,0)
962MU EP NQF 0059^^^2.16.840.1.113883.3.249.11.2
963"DATA",1130580001.101,45,1)
964Diabetes: Hemoglobin A1c Poor Contro
965"DATA",1130580001.101,45,4)
966PQRI-1
967"DATA",1130580001.101,45,5)
968Diabetes: NQF0059 Hemoglobin A1c Poor Control
969"DATA",1130580001.101,45,6,0)
970^^2^2^3110430^
971"DATA",1130580001.101,45,6,1,0)
972Percentage of patients 18 - 75 years of age with diabetes (type 1
973"DATA",1130580001.101,45,6,2,0)
974or type 2) who had hemoglobin A1c > 9.0%.
975"DATA",1130580001.101,45,7)
976NQF0059^^^^^^260^258
977"DATA",1130580001.101,46,0)
978MU EP NQF 0064^^^2.16.840.1.113883.3.249.11.3
979"DATA",1130580001.101,46,1)
980Diabetes: Low Density Lipoprotein (LDL) Management and Control
981"DATA",1130580001.101,46,4)
982PQRI-2
983"DATA",1130580001.101,46,5)
984NQF0064 Diabetes: Low Density Lipoprotein (LDL) Management and Control
985"DATA",1130580001.101,46,6,0)
986^^3^3^3110430^
987"DATA",1130580001.101,46,6,1,0)
988Percentage of patients 18-75 years of age with diabetes (type 1
989"DATA",1130580001.101,46,6,2,0)
990or type 2) who had LDL-C < 100 mg/dL).Percentage of patients 18-75 years
991"DATA",1130580001.101,46,6,3,0)
992of age with diabetes (type 1 or type 2) who had LDL-C < 100 mg/dL).
993"DATA",1130580001.101,46,7)
994NQF0064^^^^^^248^258
995"DATA",1130580001.101,47,0)
996MU EP NQF 0061^^^2.16.840.1.113883.3.249.11.4
997"DATA",1130580001.101,47,1)
998Blood Pressure Management
999"DATA",1130580001.101,47,4)
1000PQRI-3
1001"DATA",1130580001.101,47,5)
1002NQF0061 Diabetes: Blood Pressure Management
1003"DATA",1130580001.101,47,6,0)
1004^^2^2^3110430^
1005"DATA",1130580001.101,47,6,1,0)
1006Percentage of patients 18 - 75 years of age with
1007"DATA",1130580001.101,47,6,2,0)
1008diabetes (type 1 or type 2) who had blood pressure <140/90 mmHg.
1009"DATA",1130580001.101,47,7)
1010NQF0061^^^^^^262^258
1011"DATA",1130580001.101,48,0)
1012MU EP NQF 0081^^^2.16.840.1.113883.3.249.11.5
1013"DATA",1130580001.101,48,1)
1014Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
1015"DATA",1130580001.101,48,4)
1016PQRI-5
1017"DATA",1130580001.101,48,5)
1018Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
1019"DATA",1130580001.101,48,6,0)
1020^^3^3^3110430^
1021"DATA",1130580001.101,48,6,1,0)
1022Percentage of patients aged 18 years and older with a
1023"DATA",1130580001.101,48,6,2,0)
1024diagnosis of heart failure and LVSD (LVEF < 40%) who were
1025"DATA",1130580001.101,48,6,3,0)
1026prescribed ACE inhibitor or ARB therapy
1027"DATA",1130580001.101,48,7)
1028NQF0081
1029"DATA",1130580001.101,49,0)
1030MU EP NQF 0070^^^2.16.840.1.113883.3.249.11.6
1031"DATA",1130580001.101,49,1)
1032CMS Measure #7: Coronary Artery Disease (CAD): Beta-Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI)
1033"DATA",1130580001.101,49,4)
1034PQRI-7
1035"DATA",1130580001.101,49,5)
1036Percentage of patients 18 aged 18 years and older wit a diagnosis of CAD and prior MI who were prescribed beta-blocker therapy
1037"DATA",1130580001.101,49,6,0)
1038^^3^3^3101013^
1039"DATA",1130580001.101,49,6,1,0)
1040Percentage of patients aged 18 years and older with a diagnosis of
1041"DATA",1130580001.101,49,6,2,0)
1042coronary artery disease and a prior MI who where prescribed beta-blocker
1043"DATA",1130580001.101,49,6,3,0)
1044therapy
1045"DATA",1130580001.101,49,7)
1046NQF0070
1047"DATA",1130580001.101,50,0)
1048MU EP NQF 0031^^^2.16.840.1.113883.3.249.11.9
1049"DATA",1130580001.101,50,1)
1050Breast Cancer Screening
1051"DATA",1130580001.101,50,4)
1052PQRI-112
1053"DATA",1130580001.101,50,5)
1054Breast Cancer Screening
1055"DATA",1130580001.101,50,6,0)
1056^^2^2^3110430^
1057"DATA",1130580001.101,50,6,1,0)
1058Percentage of women 40-69 years of age who had a
1059"DATA",1130580001.101,50,6,2,0)
1060mammogram to screen for breast cancer
1061"DATA",1130580001.101,50,7)
1062NQF0031
1063"DATA",1130580001.101,51,0)
1064MU EP NQF 0034^^^2.16.840.1.113883.3.249.11.10
1065"DATA",1130580001.101,51,1)
1066Colorectal Cancer Screening
1067"DATA",1130580001.101,51,4)
1068PQRI-113
1069"DATA",1130580001.101,51,5)
1070Colorectal Cancer Screening
1071"DATA",1130580001.101,51,6,0)
1072^^2^2^3110430^
1073"DATA",1130580001.101,51,6,1,0)
1074Percentage of adults 50-75 years of age who had appropriate screening for
1075"DATA",1130580001.101,51,6,2,0)
1076colorectal cancer.
1077"DATA",1130580001.101,51,7)
1078NQF0034
1079"DATA",1130580001.101,52,0)
1080MU EP NQF 0067
1081"DATA",1130580001.101,52,1)
1082Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD
1083"DATA",1130580001.101,52,5)
1084Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD
1085"DATA",1130580001.101,52,6,0)
1086^^2^2^3110430^
1087"DATA",1130580001.101,52,6,1,0)
1088Percentage of patients aged 18 years and older with a
1089"DATA",1130580001.101,52,6,2,0)
1090diagnosis of CAD who were prescribed oral antiplatelet therapy.
1091"DATA",1130580001.101,52,7)
1092NQF0067
1093"DATA",1130580001.101,53,0)
1094MU EP NQF 0083
1095"DATA",1130580001.101,53,1)
1096Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)
1097"DATA",1130580001.101,53,5)
1098Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)
1099"DATA",1130580001.101,53,6,0)
1100^^3^3^3110430^
1101"DATA",1130580001.101,53,6,1,0)
1102Percentage of patients aged 18 years and older with a
1103"DATA",1130580001.101,53,6,2,0)
1104diagnosis of heart failure who also have LVSD (LVEF < 40%) and who were
1105"DATA",1130580001.101,53,6,3,0)
1106prescribed beta-blocker therapy
1107"DATA",1130580001.101,53,7)
1108NQF0083
1109"DATA",1130580001.101,54,0)
1110MU EP NQF 0105
1111"DATA",1130580001.101,54,1)
1112Anti-depressant medication management: (a) Effective Acute Phase Treatment,(b)Effective Continuation Phase Treatment
1113"DATA",1130580001.101,54,5)
1114Anti-depressant medication management: (a) Effective Acute Phase Treatment,(b)Effective Continuation Phase Treatment
1115"DATA",1130580001.101,54,6,0)
1116^^4^4^3110430^
1117"DATA",1130580001.101,54,6,1,0)
1118The percentage of patients 18 years of age and older
1119"DATA",1130580001.101,54,6,2,0)
1120who were diagnosed with a new episode of major depression, treated
1121"DATA",1130580001.101,54,6,3,0)
1122with antidepressant medication, and who remained on an
1123"DATA",1130580001.101,54,6,4,0)
1124antidepressant medication treatment.
1125"DATA",1130580001.101,54,7)
1126NQF0105
1127"DATA",1130580001.101,55,0)
1128MU EP NQF 0086
1129"DATA",1130580001.101,55,1)
1130Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation
1131"DATA",1130580001.101,55,5)
1132Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation
1133"DATA",1130580001.101,55,6,0)
1134^^4^4^3110430^
1135"DATA",1130580001.101,55,6,1,0)
1136Percentage of patients aged 18 years and older with a
1137"DATA",1130580001.101,55,6,2,0)
1138diagnosis of POAG who have been seen for at least two office visits
1139"DATA",1130580001.101,55,6,3,0)
1140who have an optic nerve head evaluation during one or more office
1141"DATA",1130580001.101,55,6,4,0)
1142visits within 12 months.
1143"DATA",1130580001.101,55,7)
1144NQF0086
1145"DATA",1130580001.101,56,0)
1146MU EP NQF 0088
1147"DATA",1130580001.101,56,1)
1148Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy
1149"DATA",1130580001.101,56,5)
1150Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy
1151"DATA",1130580001.101,56,6,0)
1152^^5^5^3110430^
1153"DATA",1130580001.101,56,6,1,0)
1154Percentage of patients aged 18 years and older with a
1155"DATA",1130580001.101,56,6,2,0)
1156diagnosis of diabetic retinopathy who had a dilated macular or fundus
1157"DATA",1130580001.101,56,6,3,0)
1158exam performed which included documentation of the level of severity
1159"DATA",1130580001.101,56,6,4,0)
1160of retinopathy and the presence or absence of macular edema during
1161"DATA",1130580001.101,56,6,5,0)
1162one or more office visits within 12 months.
1163"DATA",1130580001.101,56,7)
1164NQF0088
1165"DATA",1130580001.101,57,0)
1166MU EP NQF 0089
1167"DATA",1130580001.101,57,1)
1168Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care
1169"DATA",1130580001.101,57,5)
1170Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care
1171"DATA",1130580001.101,57,6,0)
1172^^6^6^3110430^
1173"DATA",1130580001.101,57,6,1,0)
1174Percentage of patients aged 18 years and older with a
1175"DATA",1130580001.101,57,6,2,0)
1176diagnosis of diabetic retinopathy who had a dilated macular or fundus
1177"DATA",1130580001.101,57,6,3,0)
1178exam performed with documented communication to the physician who
1179"DATA",1130580001.101,57,6,4,0)
1180manages the ongoing care of the patient with diabetes mellitus
1181"DATA",1130580001.101,57,6,5,0)
1182regarding the findings of the macular or fundus exam at least once
1183"DATA",1130580001.101,57,6,6,0)
1184within 12 months.
1185"DATA",1130580001.101,57,7)
1186NQF0089
1187"DATA",1130580001.101,58,0)
1188MU EP NQF 0047
1189"DATA",1130580001.101,58,1)
1190Asthma Pharmacologic Therapy
1191"DATA",1130580001.101,58,5)
1192Asthma Pharmacologic Therapy
1193"DATA",1130580001.101,58,6,0)
1194^1130580001.111^4^4^3110430^^
1195"DATA",1130580001.101,58,6,1,0)
1196Percentage of patients aged 5 through 40 years with a
1197"DATA",1130580001.101,58,6,2,0)
1198diagnosis of mild, moderate, or severe persistent asthma who were
1199"DATA",1130580001.101,58,6,3,0)
1200prescribed either the preferred long-term control medication (inhaled
1201"DATA",1130580001.101,58,6,4,0)
1202corticosteroid) or an acceptable alternative treatment
1203"DATA",1130580001.101,58,7)
1204NQF0047
1205"DATA",1130580001.101,59,0)
1206MU EP NQF 0001
1207"DATA",1130580001.101,59,1)
1208Asthma Assessment
1209"DATA",1130580001.101,59,5)
1210Asthma Assessment
1211"DATA",1130580001.101,59,6,0)
1212^^5^5^3110430^
1213"DATA",1130580001.101,59,6,1,0)
1214Percentage of patients aged 5 through 40 years with a
1215"DATA",1130580001.101,59,6,2,0)
1216diagnosis of asthma and who have been seen for at least 2 office
1217"DATA",1130580001.101,59,6,3,0)
1218visits, who were evaluated during at least one office visit within 12
1219"DATA",1130580001.101,59,6,4,0)
1220months for the frequency (numeric) of daytime and nocturnal asthma
1221"DATA",1130580001.101,59,6,5,0)
1222symptoms.
1223"DATA",1130580001.101,59,7)
1224NQF0001
1225"DATA",1130580001.101,60,0)
1226MU EP NQF 0002
1227"DATA",1130580001.101,60,1)
1228Oncology Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breat Cancer
1229"DATA",1130580001.101,60,5)
1230Oncology Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer
1231"DATA",1130580001.101,60,6,0)
1232^^4^4^3110430^
1233"DATA",1130580001.101,60,6,1,0)
1234Percentage of female patients aged 18 years and older
1235"DATA",1130580001.101,60,6,2,0)
1236with Stage IC through IIIC, ER or PR positive breast cancer who were
1237"DATA",1130580001.101,60,6,3,0)
1238prescribed tamoxifen or aromatase inhibitor (AI) during the 12-month
1239"DATA",1130580001.101,60,6,4,0)
1240reporting period.
1241"DATA",1130580001.101,60,7)
1242NQF0002
1243"DATA",1130580001.101,61,0)
1244MU EP NQF 0385
1245"DATA",1130580001.101,61,1)
1246Oncology Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients
1247"DATA",1130580001.101,61,5)
1248Oncology Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients
1249"DATA",1130580001.101,61,6,0)
1250^^4^4^3110430^
1251"DATA",1130580001.101,61,6,1,0)
1252Percentage of patients aged 18 years and older with
1253"DATA",1130580001.101,61,6,2,0)
1254Stage IIIA through IIIC colon cancer who are referred for adjuvant
1255"DATA",1130580001.101,61,6,3,0)
1256chemotherapy, prescribed adjuvant chemotherapy, or have previously
1257"DATA",1130580001.101,61,6,4,0)
1258received adjuvant chemotherapy within the 12-month reporting period
1259"DATA",1130580001.101,61,7)
1260NQF0385
1261"DATA",1130580001.101,62,0)
1262MU EP NQF 0389
1263"DATA",1130580001.101,62,1)
1264Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients
1265"DATA",1130580001.101,62,5)
1266Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients
1267"DATA",1130580001.101,62,6,0)
1268^^5^5^3110430^
1269"DATA",1130580001.101,62,6,1,0)
1270Percentage of patients, regardless of age, with a diagnosis of
1271"DATA",1130580001.101,62,6,2,0)
1272prostate cancer at low risk of recurrence receiving interstitial prostate
1273"DATA",1130580001.101,62,6,3,0)
1274brachytherapy, OR external beam radiotherapy to the prostate, OR radical
1275"DATA",1130580001.101,62,6,4,0)
1276prostatectomy, OR cryotherapy who did not have a bone scan performed at
1277"DATA",1130580001.101,62,6,5,0)
1278any time since diagnosis of prostate cancer.
1279"DATA",1130580001.101,62,7)
1280NQF0389
1281"DATA",1130580001.101,63,0)
1282MU EP NQF 0027
1283"DATA",1130580001.101,63,1)
1284Smoking Smokers and Tobacco Users to Quit,b. Discussing Smoking and Tobacco use Cessation Medications, c. Discussing Smoking and Tobacco use Cessation Strategies and Tobacco Use Cessation, Medical assistance: a. Advising
1285"DATA",1130580001.101,63,5)
1286Smoking and Tobacco Use Cessation
1287"DATA",1130580001.101,63,6,0)
1288^^5^5^3110430^
1289"DATA",1130580001.101,63,6,1,0)
1290Percentage of patients 18 years of age and older who were
1291"DATA",1130580001.101,63,6,2,0)
1292current smokers or tobacco users, who were seen by a practitioner during
1293"DATA",1130580001.101,63,6,3,0)
1294the measurement year and who received advice to quit smoking or tobacco
1295"DATA",1130580001.101,63,6,4,0)
1296use or whose practitioner recommended or discussed smoking or tobacco use
1297"DATA",1130580001.101,63,6,5,0)
1298cessation medications, methods or strategies
1299"DATA",1130580001.101,63,7)
1300NQF0027
1301"DATA",1130580001.101,64,0)
1302MU EP NQF 0055
1303"DATA",1130580001.101,64,1)
1304Diabetes: Eye Exam
1305"DATA",1130580001.101,64,5)
1306Diabetes: Eye Exam
1307"DATA",1130580001.101,64,6,0)
1308^^3^3^3110430^
1309"DATA",1130580001.101,64,6,1,0)
1310Percentage of patients 18 -75 years of age with diabetes (type 1
1311"DATA",1130580001.101,64,6,2,0)
1312or type 2) who had a retinal or dilated eye exam or a negative retinal
1313"DATA",1130580001.101,64,6,3,0)
1314exam (no evidence of retinopathy) by an eye care professional
1315"DATA",1130580001.101,64,7)
1316NQF0055
1317"DATA",1130580001.101,65,0)
1318MU EP NQF 0062
1319"DATA",1130580001.101,65,1)
1320Diabetes: Urine Screening
1321"DATA",1130580001.101,65,5)
1322Diabetes: Urine Screening
1323"DATA",1130580001.101,65,6,0)
1324^^3^3^3110430^
1325"DATA",1130580001.101,65,6,1,0)
1326Percentage of patients 18 - 75 years of age with diabetes (type 1
1327"DATA",1130580001.101,65,6,2,0)
1328or type 2) who had a nephropathy screening test or evidence of
1329"DATA",1130580001.101,65,6,3,0)
1330nephropathy.
1331"DATA",1130580001.101,65,7)
1332NQF0062
1333"DATA",1130580001.101,66,0)
1334MU EP NQF 0056
1335"DATA",1130580001.101,66,1)
1336Diabetes: Foot Exam
1337"DATA",1130580001.101,66,5)
1338Diabetes: Foot Exam
1339"DATA",1130580001.101,66,6,0)
1340^^3^3^3110430^
1341"DATA",1130580001.101,66,6,1,0)
1342The percentage of patients aged 18 - 75 years with diabetes
1343"DATA",1130580001.101,66,6,2,0)
1344(type 1 or type 2) who had a foot exam (visual inspection, sensory exam
1345"DATA",1130580001.101,66,6,3,0)
1346with monofilament, or pulse exam).
1347"DATA",1130580001.101,66,7)
1348NQF0056
1349"DATA",1130580001.101,67,0)
1350MU EP NQF 0074
1351"DATA",1130580001.101,67,1)
1352Coronary Artery Disease (CAD): Drug Therapy for Lowering LDLCholesterol
1353"DATA",1130580001.101,67,5)
1354Coronary Artery Disease (CAD): Drug Therapy for Lowering LDLCholesterol
1355"DATA",1130580001.101,67,6,0)
1356^^3^3^3110430^
1357"DATA",1130580001.101,67,6,1,0)
1358Percentage of patients aged 18 years and older with a
1359"DATA",1130580001.101,67,6,2,0)
1360diagnosis of CAD who were prescribed a lipid-lowering therapy (based
1361"DATA",1130580001.101,67,6,3,0)
1362on current ACC/AHA guidelines).
1363"DATA",1130580001.101,67,7)
1364NQF0074
1365"DATA",1130580001.101,68,0)
1366MU EP NQF 0084
1367"DATA",1130580001.101,68,1)
1368Heart Failure (HF): Warfarin Therapy Patients with Atrial Fibrillation
1369"DATA",1130580001.101,68,5)
1370Heart Failure (HF): Warfarin Therapy Patients with Atrial Fibrillation
1371"DATA",1130580001.101,68,6,0)
1372^^3^3^3110430^
1373"DATA",1130580001.101,68,6,1,0)
1374Percentage of all patients aged 18 years and older with a
1375"DATA",1130580001.101,68,6,2,0)
1376diagnosis of heart failure and paroxysmal or chronic atrial fibrillation
1377"DATA",1130580001.101,68,6,3,0)
1378who were prescribed warfarin therapy.
1379"DATA",1130580001.101,68,7)
1380NQF0084
1381"DATA",1130580001.101,69,0)
1382MU EP NQF 0073
1383"DATA",1130580001.101,69,1)
1384Ischemic Vascular Disease (IVD): Blood Pressure Management
1385"DATA",1130580001.101,69,5)
1386Ischemic Vascular Disease (IVD): Blood Pressure Management
1387"DATA",1130580001.101,69,6,0)
1388^^11^11^3110430^
1389"DATA",1130580001.101,69,6,1,0)
1390Percentage of patients 18 years of age and older who
1391"DATA",1130580001.101,69,6,2,0)
1392were discharged alive for acute myocardial infarction (AMI), coronary
1393"DATA",1130580001.101,69,6,3,0)
1394artery bypass graft (CABG) or percutaneous transluminal coronary
1395"DATA",1130580001.101,69,6,4,0)
1396Percentage of patients 18 years of age and older who
1397"DATA",1130580001.101,69,6,5,0)
1398were discharged alive for acute myocardial infarction (AMI), coronary
1399"DATA",1130580001.101,69,6,6,0)
1400artery bypass graft (CABG) or percutaneous transluminal coronary
1401"DATA",1130580001.101,69,6,7,0)
1402angioplasty (PTCA) from January 1- November 1 of the year prior to
1403"DATA",1130580001.101,69,6,8,0)
1404the measurement year, or who had a diagnosis of ischemic vascular
1405"DATA",1130580001.101,69,6,9,0)
1406disease (IVD) during the measurement year and the year prior to the
1407"DATA",1130580001.101,69,6,10,0)
1408measurement year and whose recent blood pressure is in control
1409"DATA",1130580001.101,69,6,11,0)
1410(<140/90 mmHg).
1411"DATA",1130580001.101,69,7)
1412NQF0073
1413"DATA",1130580001.101,70,0)
1414MU EP NQF 0068
1415"DATA",1130580001.101,70,1)
1416Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic
1417"DATA",1130580001.101,70,5)
1418 Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic
1419"DATA",1130580001.101,70,6,0)
1420^^8^8^3110430^
1421"DATA",1130580001.101,70,6,1,0)
1422 Percentage of patients 18 years of age and older who were
1423"DATA",1130580001.101,70,6,2,0)
1424discharged alive for acute myocardial infarction (AMI), coronary artery
1425"DATA",1130580001.101,70,6,3,0)
1426bypass graft (CABG) or percutaneous transluminal coronary
1427"DATA",1130580001.101,70,6,4,0)
1428angioplasty (PTCA) from January 1-November 1 of the year prior to the
1429"DATA",1130580001.101,70,6,5,0)
1430measurement year, or who had a diagnosis of ischemic vascular
1431"DATA",1130580001.101,70,6,6,0)
1432disease (IVD) during the measurement year and the year prior to the
1433"DATA",1130580001.101,70,6,7,0)
1434measurement year and who had documentation of use of aspirin or
1435"DATA",1130580001.101,70,6,8,0)
1436another antithrombotic during the measurement year
1437"DATA",1130580001.101,70,7)
1438NQF0068
1439"DATA",1130580001.101,71,0)
1440MU EP NQF 0004
1441"DATA",1130580001.101,71,1)
1442 Initiation and Engagement of Alcohol and Other Drug Dependence Treatment:(a)Initiation,(b)Engagement
1443"DATA",1130580001.101,71,5)
1444Initiation and Engagement of Alcohol and Other Drug Dependence Treatment:(a) Initiation,(b) Engagement
1445"DATA",1130580001.101,71,6,0)
1446^^6^6^3110430^
1447"DATA",1130580001.101,71,6,1,0)
1448The percentage of adolescent and adult patients with a new
1449"DATA",1130580001.101,71,6,2,0)
1450episode of alcohol and other drug (AOD) dependence who initiate treatment
1451"DATA",1130580001.101,71,6,3,0)
1452through an inpatient AOD admission, outpatient visit, intensive
1453"DATA",1130580001.101,71,6,4,0)
1454outpatient encounter or partial hospitalization within 14 days of the
1455"DATA",1130580001.101,71,6,5,0)
1456diagnosis and who initiated treatment and who had two or more additional
1457"DATA",1130580001.101,71,6,6,0)
1458services with an AOD diagnosis within 30 days of the initiation visit.
1459"DATA",1130580001.101,71,7)
1460NQF0004
1461"DATA",1130580001.101,72,0)
1462MU EP NQF 0012
1463"DATA",1130580001.101,72,1)
1464Prenatal Care: Screening for Human Immunodeficiency Virus (HIV)
1465"DATA",1130580001.101,72,5)
1466Prenatal Care: Screening for Human Immunodeficiency Virus (HIV)
1467"DATA",1130580001.101,72,6,0)
1468^^3^3^3110430^
1469"DATA",1130580001.101,72,6,1,0)
1470Percentage of patients, regardless of age, who gave birth during
1471"DATA",1130580001.101,72,6,2,0)
1472a 12-month period who were screened for HIV infection during the first or
1473"DATA",1130580001.101,72,6,3,0)
1474second prenatal care visit.
1475"DATA",1130580001.101,72,7)
1476NQF0012
1477"DATA",1130580001.101,73,0)
1478MU EP NQF 0014
1479"DATA",1130580001.101,73,1)
1480Prenatal Care: Anti-D Immune Globulin
1481"DATA",1130580001.101,73,5)
1482Prenatal Care: Anti-D Immune Globulin
1483"DATA",1130580001.101,73,6,0)
1484^^3^3^3110430^
1485"DATA",1130580001.101,73,6,1,0)
1486Percentage of D (Rh) negative, unsensitized patients, regardless
1487"DATA",1130580001.101,73,6,2,0)
1488of age, who gave birth during a 12-month period who received anti-D
1489"DATA",1130580001.101,73,6,3,0)
1490immune globulin at 26-30 weeks gestation.
1491"DATA",1130580001.101,73,7)
1492NQD0014
1493"DATA",1130580001.101,74,0)
1494MU EP NQF 0018
1495"DATA",1130580001.101,74,1)
1496Controlling High Blood Pressure
1497"DATA",1130580001.101,74,5)
1498Controlling High Blood Pressure
1499"DATA",1130580001.101,74,6,0)
1500^^3^3^3110430^
1501"DATA",1130580001.101,74,6,1,0)
1502The percentage of patients 18-85 years of age who had a
1503"DATA",1130580001.101,74,6,2,0)
1504diagnosis of hypertension and whose BP was adequately controlled during
1505"DATA",1130580001.101,74,6,3,0)
1506the measurement year
1507"DATA",1130580001.101,74,7)
1508NQF0018
1509"DATA",1130580001.101,75,0)
1510MU EP NQF 0032
1511"DATA",1130580001.101,75,1)
1512Cervical Cancer Screening
1513"DATA",1130580001.101,75,5)
1514Cervical Cancer Screening
1515"DATA",1130580001.101,75,6,0)
1516^^2^2^3110430^
1517"DATA",1130580001.101,75,6,1,0)
1518Percentage of women 21-64 years of age, who received one or
1519"DATA",1130580001.101,75,6,2,0)
1520more Pap tests to screen for cervical cancer
1521"DATA",1130580001.101,75,7)
1522NQF0032
1523"DATA",1130580001.101,76,0)
1524MU EP NQF 0033
1525"DATA",1130580001.101,76,1)
1526Chlamydia Screening for Women
1527"DATA",1130580001.101,76,5)
1528Chlamydia Screening for Women
1529"DATA",1130580001.101,76,6,0)
1530^^3^3^3110430^
1531"DATA",1130580001.101,76,6,1,0)
1532Percentage of women 15- 24 years of age who were identified as sexually
1533"DATA",1130580001.101,76,6,2,0)
1534active and who had at least one test for chlamydia during the measurement
1535"DATA",1130580001.101,76,6,3,0)
1536year.
1537"DATA",1130580001.101,76,7)
1538NQF0033
1539"DATA",1130580001.101,77,0)
1540MU EP NQF 0036
1541"DATA",1130580001.101,77,1)
1542Use of Appropriate Medications for Asthma
1543"DATA",1130580001.101,77,5)
1544Use of Appropriate Medications for Asthma
1545"DATA",1130580001.101,77,6,0)
1546^^4^4^3110430^
1547"DATA",1130580001.101,77,6,1,0)
1548Percentage of patients 5 - 50 years of age who were identified as having
1549"DATA",1130580001.101,77,6,2,0)
1550persistent asthma and were appropriately prescribed medication during the
1551"DATA",1130580001.101,77,6,3,0)
1552measurement year. Report three age stratifications (5-11 years, 12-50
1553"DATA",1130580001.101,77,6,4,0)
1554years, and total).
1555"DATA",1130580001.101,77,7)
1556NQF0036
1557"DATA",1130580001.101,78,0)
1558MU EP NQF 0052
1559"DATA",1130580001.101,78,1)
1560Low Back Pain: Use of Imaging Studies
1561"DATA",1130580001.101,78,5)
1562Low Back Pain: Use of Imaging Studies
1563"DATA",1130580001.101,78,6,0)
1564^1130580001.111^3^3^3110430^^
1565"DATA",1130580001.101,78,6,1,0)
1566Percentage of patients with a primary diagnosis of low back pain
1567"DATA",1130580001.101,78,6,2,0)
1568who did not have an imaging study (plain x-ray, MRI, CT scan) within 28
1569"DATA",1130580001.101,78,6,3,0)
1570days of diagnosis.
1571"DATA",1130580001.101,78,7)
1572NQF0052
1573"DATA",1130580001.101,79,0)
1574MU EP NQF 0075
1575"DATA",1130580001.101,79,1)
1576Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control
1577"DATA",1130580001.101,79,5)
1578Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control
1579"DATA",1130580001.101,79,6,0)
1580^^7^7^3110430^
1581"DATA",1130580001.101,79,6,1,0)
1582Percentage of patients 18 years of age and older who were discharged alive
1583"DATA",1130580001.101,79,6,2,0)
1584for acute myocardial infarction (AMI), coronary artery bypass graft (CABG)
1585"DATA",1130580001.101,79,6,3,0)
1586or percutaneous transluminal angioplasty (PTCA) from January 1-November1
1587"DATA",1130580001.101,79,6,4,0)
1588of the year prior to the measurement year, or who had a diagnosis of
1589"DATA",1130580001.101,79,6,5,0)
1590ischemic vascular disease (IVD) during the measurement year and the year
1591"DATA",1130580001.101,79,6,6,0)
1592prior to the measurement year and who had a complete lipid profile
1593"DATA",1130580001.101,79,6,7,0)
1594performed during the measurement year and whose LDL-C<100 mg/dL
1595"DATA",1130580001.101,79,7)
1596NQF0075
1597"DATA",1130580001.101,80,0)
1598MU EP NQF 0575
1599"DATA",1130580001.101,80,1)
1600Diabetes: Hemoglobin A1c Control (<8.0%)
1601"DATA",1130580001.101,80,5)
1602Diabetes: Hemoglobin A1c Control (<8.0%)
1603"DATA",1130580001.101,80,6,0)
1604^^2^2^3110430^
1605"DATA",1130580001.101,80,6,1,0)
1606The percentage of patients 18-75 years of age with diabetes
1607"DATA",1130580001.101,80,6,2,0)
1608(type 1 or type 2) who had hemoglobin A1c <8.0%
1609"DATA",1130580001.101,80,7)
1610NQF0575
1611"DATA",1130580001.101,81,0)
1612MU EP NQF 0028B
1613"DATA",1130580001.101,81,1)
1614NQF0028B Preventive Care and Screening Measure Pair: a. Tobacco Use Assessment,b. Tobacco Cessation Intervention
1615"DATA",1130580001.101,81,5)
1616NQF0028B Tobacco Use Assessment and Cessation Intervention
1617"DATA",1130580001.101,81,6,0)
1618^1130580001.111^7^7^3110625^^^^
1619"DATA",1130580001.101,81,6,1,0)
1620 Percentage of patients aged 18 years and
1621"DATA",1130580001.101,81,6,2,0)
1622older who have been seen for at least 2 office visits who
1623"DATA",1130580001.101,81,6,3,0)
1624were queried about tobacco use one or more times within
1625"DATA",1130580001.101,81,6,4,0)
162624 months b. Percentage of patients aged 18 years and
1627"DATA",1130580001.101,81,6,5,0)
1628older identified as tobacco users within the past 24
1629"DATA",1130580001.101,81,6,6,0)
1630months and have been seen for at least 2 office visits,
1631"DATA",1130580001.101,81,6,7,0)
1632who received cessation intervention.
1633"DATA",1130580001.101,81,7)
1634NQF0028B^^^^^^154^160
1635"DATA",1130580001.101,82,0)
1636MU EP NQF 0024 2-10Y
1637"DATA",1130580001.101,82,1)
1638NQF0024 Weight Assessment and Counseling for Children and Adolescents (2-10)
1639"DATA",1130580001.101,82,5)
1640Weight Assessment and Counseling for Children 2-10 Years Old
1641"DATA",1130580001.101,82,6,0)
1642^^6^6^3120803^
1643"DATA",1130580001.101,82,6,1,0)
1644Percentage of patients 2-10 years of age
1645"DATA",1130580001.101,82,6,2,0)
1646who had an outpatient visit with a Primary Care Physician
1647"DATA",1130580001.101,82,6,3,0)
1648(PCP) or OB/GYN and who had evidence of BMI
1649"DATA",1130580001.101,82,6,4,0)
1650percentile documentation, counseling for nutrition and
1651"DATA",1130580001.101,82,6,5,0)
1652counseling for physical activity during the measurement
1653"DATA",1130580001.101,82,6,6,0)
1654year. Only for those 2-10 years of age.
1655"DATA",1130580001.101,82,7)
1656NQF0024 2-10Y^^^^^^334^338
1657"DATA",1130580001.101,83,0)
1658MU EP NQF 0038 NUM1 DPT
1659"DATA",1130580001.101,83,5)
1660NQF0038 NUM1 DPT
1661"DATA",1130580001.101,83,7)
1662NQF0038 NUM1 DPT^^^^^^329^192^11
1663"DATA",1130580001.101,84,0)
1664MU EP NQF 0038 NUM2 IPV
1665"DATA",1130580001.101,84,5)
1666NQF0038 NUM2 IPV
1667"DATA",1130580001.101,84,7)
1668NQF0038 NUM2 IPV^^^^^^224^192^11
1669"DATA",1130580001.101,85,0)
1670MU EP NQF 0038 NUM3 MMR
1671"DATA",1130580001.101,85,5)
1672NQF0038 NUM3 MMR
1673"DATA",1130580001.101,85,7)
1674NQF0038 NUM3 MMR^^^^^^183^192^11
1675"DATA",1130580001.101,86,0)
1676MU EP NQF 0038 NUM4 HiB
1677"DATA",1130580001.101,86,5)
1678NQF0038 NUM4 HiB
1679"DATA",1130580001.101,86,7)
1680NQF0038 NUM4 HiB^^^^^^189^192^11
1681"DATA",1130580001.101,87,0)
1682MU EP NQF 0038 NUM5 HEP B
1683"DATA",1130580001.101,87,5)
1684NQF0038 NUM5 HEP B
1685"DATA",1130580001.101,87,7)
1686NQF0038 NUM5 HEP B^^^^^^194^192^11
1687"DATA",1130580001.101,88,0)
1688MU EP NQF 0038 NUM6 VZV
1689"DATA",1130580001.101,88,5)
1690NQF0038 NUM6 VZV
1691"DATA",1130580001.101,88,7)
1692NQF0038 NUM6 VZV^^^^^^198^192^11
1693"DATA",1130580001.101,89,0)
1694MU EP NQF 0038 NUM7 PCV
1695"DATA",1130580001.101,89,5)
1696NQF0038 NUM7 PCV
1697"DATA",1130580001.101,89,7)
1698NQF0038 NUM7 PCV^^^^^^205^192^11
1699"DATA",1130580001.101,90,0)
1700MU EP NQF 0038 NUM8 HEP A
1701"DATA",1130580001.101,90,5)
1702NQF0038 NUM8 HEP A
1703"DATA",1130580001.101,90,7)
1704NQF0038 NUM8 HEP A^^^^^^208^192^11
1705"DATA",1130580001.101,91,0)
1706MU EP NQF 0038 NUM9 RV
1707"DATA",1130580001.101,91,5)
1708NQF0038 NUM9
1709"DATA",1130580001.101,91,7)
1710NQF0038 NUM9^^^^^^216^192^11
1711"DATA",1130580001.101,92,0)
1712MU EP NQF 0038 NUM10 FLU
1713"DATA",1130580001.101,92,5)
1714NQF0038 NUM10
1715"DATA",1130580001.101,92,7)
1716NQF0038 NUM10^^^^^^331^192^11
1717"DATA",1130580001.101,93,0)
1718MU EP NQF 0038 NUM11 COMBO5
1719"DATA",1130580001.101,93,5)
1720NQF0038 NUM11 COMBO5
1721"DATA",1130580001.101,93,7)
1722NQF0038 NUM11 COMBO5^^^^^^228^192^11
1723"DATA",1130580001.101,94,0)
1724MU EP NQF 0038 NUM12 COMBO6
1725"DATA",1130580001.101,94,5)
1726NQF0038 NUM12 COMBO6
1727"DATA",1130580001.101,94,7)
1728NQF0038 NUM12 COMBO6^^^^^^231^192^11
1729"DATA",1130580001.101,95,0)
1730MU 2011 INP ADV DIRECTIVES
1731"DATA",1130580001.101,95,5)
1732Advance Directives
1733"DATA",1130580001.101,96,0)
1734MU 2011 INP CPOE
1735"DATA",1130580001.101,96,5)
1736CPOE for Medications
1737"DATA",1130580001.101,97,0)
1738MU 2011 INP MED RECON
1739"DATA",1130580001.101,97,5)
1740Medication Reconcilliation
1741"DATA",1130580001.101,98,0)
1742MU 2011 INP PROBLEM LIST
1743"DATA",1130580001.101,98,5)
1744Problem List
1745"DATA",1130580001.101,99,0)
1746MU 2011 INP VITAL SIGNS
1747"DATA",1130580001.101,99,5)
1748Record Vital Signs
1749"DATA",1130580001.101,100,0)
1750MU 2011 INP SMOKING STATUS
1751"DATA",1130580001.101,100,5)
1752Smoking Status
1753"DATA",1130580001.101,101,0)
1754MU 2011 INP MED LIST
1755"DATA",1130580001.101,101,5)
1756Active Medication List
1757"DATA",1130580001.101,102,0)
1758MU 2011 INP ALLERGY LIST
1759"DATA",1130580001.101,102,5)
1760Medication Allergy List
1761"DATA",1130580001.101,103,0)
1762MU 2011 INP DEMOGRAPHICS
1763"DATA",1130580001.101,103,5)
1764Record Demographics
1765"DATA",1130580001.101,104,0)
1766MU EP NQF 0024 11-17Y
1767"DATA",1130580001.101,104,1)
1768NQF0024 Weight Assessment and Counseling for Children and Adolescents (11-17)
1769"DATA",1130580001.101,104,5)
1770Weight Assessment and Counseling for Children and Adolescents 11-17 years old
1771"DATA",1130580001.101,104,6,0)
1772^^6^6^3120803^
1773"DATA",1130580001.101,104,6,1,0)
1774Percentage of patients 11-17 years of age
1775"DATA",1130580001.101,104,6,2,0)
1776who had an outpatient visit with a Primary Care Physician
1777"DATA",1130580001.101,104,6,3,0)
1778(PCP) or OB/GYN and who had evidence of BMI
1779"DATA",1130580001.101,104,6,4,0)
1780percentile documentation, counseling for nutrition and
1781"DATA",1130580001.101,104,6,5,0)
1782counseling for physical activity during the measurement
1783"DATA",1130580001.101,104,6,6,0)
1784year. Only for those 11-17 years old.
1785"DATA",1130580001.101,104,7)
1786NQF0024 11-17Y^^^^^^336^340
1787"FIA",1130580001.101)
1788C0Q QUALITY MEASURE
1789"FIA",1130580001.101,0)
1790^C0Q(101,
1791"FIA",1130580001.101,0,0)
17921130580001.101I
1793"FIA",1130580001.101,0,1)
1794y^y^f^^y^^y^o^n
1795"FIA",1130580001.101,0,10)
1796
1797"FIA",1130580001.101,0,11)
1798
1799"FIA",1130580001.101,0,"RLRO")
1800
1801"FIA",1130580001.101,0,"VR")
18021.0^C0Q
1803"FIA",1130580001.101,1130580001.101)
18040
1805"FIA",1130580001.101,1130580001.111)
18060
1807"FRV1",1130580001.101,"104,7",7)
1808MU NQF0024 BMI PERCENTILE 11-17Y RS
1809"FRV1",1130580001.101,"104,7",7,"F")
1810;PXRM(810.4,
1811"FRV1",1130580001.101,"104,7",8)
1812MU NQF0024 BMI 11-17Y DENOM RS
1813"FRV1",1130580001.101,"104,7",8,"F")
1814;PXRM(810.4,
1815"FRV1",1130580001.101,"23,7",7)
1816MU ED-1 NUMER RS
1817"FRV1",1130580001.101,"23,7",7,"F")
1818;PXRM(810.4,
1819"FRV1",1130580001.101,"23,7",8)
1820MU ED-1 DENOM RS
1821"FRV1",1130580001.101,"23,7",8,"F")
1822;PXRM(810.4,
1823"FRV1",1130580001.101,"24,7",7)
1824MU ED-2 NUMER RS
1825"FRV1",1130580001.101,"24,7",7,"F")
1826;PXRM(810.4,
1827"FRV1",1130580001.101,"24,7",8)
1828MU ED-2 DENOM RS
1829"FRV1",1130580001.101,"24,7",8,"F")
1830;PXRM(810.4,
1831"FRV1",1130580001.101,"25,7",7)
1832MU STK-2 NUMER RS
1833"FRV1",1130580001.101,"25,7",7,"F")
1834;PXRM(810.4,
1835"FRV1",1130580001.101,"25,7",8)
1836MU STK-2 DENOM RS
1837"FRV1",1130580001.101,"25,7",8,"F")
1838;PXRM(810.4,
1839"FRV1",1130580001.101,"26,7",7)
1840MU STK-3 NUMER RS
1841"FRV1",1130580001.101,"26,7",7,"F")
1842;PXRM(810.4,
1843"FRV1",1130580001.101,"26,7",8)
1844MU STK-3 DENOM RS
1845"FRV1",1130580001.101,"26,7",8,"F")
1846;PXRM(810.4,
1847"FRV1",1130580001.101,"27,7",7)
1848MU STK-4 NUMER RS
1849"FRV1",1130580001.101,"27,7",7,"F")
1850;PXRM(810.4,
1851"FRV1",1130580001.101,"27,7",8)
1852MU STK-4 DENOM RS
1853"FRV1",1130580001.101,"27,7",8,"F")
1854;PXRM(810.4,
1855"FRV1",1130580001.101,"28,7",7)
1856MU STK-5 NUMER RS
1857"FRV1",1130580001.101,"28,7",7,"F")
1858;PXRM(810.4,
1859"FRV1",1130580001.101,"28,7",8)
1860MU STK-5 DENOM RS
1861"FRV1",1130580001.101,"28,7",8,"F")
1862;PXRM(810.4,
1863"FRV1",1130580001.101,"29,7",7)
1864MU STK-6 NUMER RS
1865"FRV1",1130580001.101,"29,7",7,"F")
1866;PXRM(810.4,
1867"FRV1",1130580001.101,"29,7",8)
1868MU STK-6 DENOM RS
1869"FRV1",1130580001.101,"29,7",8,"F")
1870;PXRM(810.4,
1871"FRV1",1130580001.101,"30,7",7)
1872MU STK-8 NUMER RS
1873"FRV1",1130580001.101,"30,7",7,"F")
1874;PXRM(810.4,
1875"FRV1",1130580001.101,"30,7",8)
1876MU STK-8 DENOM RS
1877"FRV1",1130580001.101,"30,7",8,"F")
1878;PXRM(810.4,
1879"FRV1",1130580001.101,"31,7",7)
1880MU STK-10 NUMER RS
1881"FRV1",1130580001.101,"31,7",7,"F")
1882;PXRM(810.4,
1883"FRV1",1130580001.101,"31,7",8)
1884MU STK-10 DENOM RS
1885"FRV1",1130580001.101,"31,7",8,"F")
1886;PXRM(810.4,
1887"FRV1",1130580001.101,"32,7",7)
1888MU VTE-1 NUMER RS
1889"FRV1",1130580001.101,"32,7",7,"F")
1890;PXRM(810.4,
1891"FRV1",1130580001.101,"32,7",8)
1892MU VTE-1 DENOM RS
1893"FRV1",1130580001.101,"32,7",8,"F")
1894;PXRM(810.4,
1895"FRV1",1130580001.101,"33,7",7)
1896MU VTE-2 NUMER RS
1897"FRV1",1130580001.101,"33,7",7,"F")
1898;PXRM(810.4,
1899"FRV1",1130580001.101,"33,7",8)
1900MU VTE-2 DENOM RS
1901"FRV1",1130580001.101,"33,7",8,"F")
1902;PXRM(810.4,
1903"FRV1",1130580001.101,"34,7",7)
1904MU VTE-3 NUMER RS
1905"FRV1",1130580001.101,"34,7",7,"F")
1906;PXRM(810.4,
1907"FRV1",1130580001.101,"34,7",8)
1908MU VTE-3 DENOM RS
1909"FRV1",1130580001.101,"34,7",8,"F")
1910;PXRM(810.4,
1911"FRV1",1130580001.101,"35,7",7)
1912MU VTE-4 NUMER RS
1913"FRV1",1130580001.101,"35,7",7,"F")
1914;PXRM(810.4,
1915"FRV1",1130580001.101,"35,7",8)
1916MU VTE-4 DENOM RS
1917"FRV1",1130580001.101,"35,7",8,"F")
1918;PXRM(810.4,
1919"FRV1",1130580001.101,"36,7",7)
1920MU VTE-5 NUMER RS
1921"FRV1",1130580001.101,"36,7",7,"F")
1922;PXRM(810.4,
1923"FRV1",1130580001.101,"36,7",8)
1924MU VTE-5 DENOM RS
1925"FRV1",1130580001.101,"36,7",8,"F")
1926;PXRM(810.4,
1927"FRV1",1130580001.101,"37,7",7)
1928MU VTE-6 NUMER RS
1929"FRV1",1130580001.101,"37,7",7,"F")
1930;PXRM(810.4,
1931"FRV1",1130580001.101,"37,7",8)
1932MU VTE-6 DENOM RS
1933"FRV1",1130580001.101,"37,7",8,"F")
1934;PXRM(810.4,
1935"FRV1",1130580001.101,"39,7",7)
1936MU NQF0421 BMI NUM ALL RS
1937"FRV1",1130580001.101,"39,7",7,"F")
1938;PXRM(810.4,
1939"FRV1",1130580001.101,"39,7",8)
1940MU NQF0421 BMI DENOM ALL RS
1941"FRV1",1130580001.101,"39,7",8,"F")
1942;PXRM(810.4,
1943"FRV1",1130580001.101,"39,7",9)
1944MU NQF0421 ADULT BMI
1945"FRV1",1130580001.101,"39,7",9,"F")
1946;PXRM(810.2,
1947"FRV1",1130580001.101,"40,7",7)
1948MU NQF0013 HTN NUMER2 RS
1949"FRV1",1130580001.101,"40,7",7,"F")
1950;PXRM(810.4,
1951"FRV1",1130580001.101,"40,7",8)
1952MU NQF0013 HTN DENOM2 RS
1953"FRV1",1130580001.101,"40,7",8,"F")
1954;PXRM(810.4,
1955"FRV1",1130580001.101,"41,7",7)
1956MU NQF0028A TOBACCO SCREEN NUM RS
1957"FRV1",1130580001.101,"41,7",7,"F")
1958;PXRM(810.4,
1959"FRV1",1130580001.101,"41,7",8)
1960MU NQF0028B TOBACCO INTERV DENOM RS
1961"FRV1",1130580001.101,"41,7",8,"F")
1962;PXRM(810.4,
1963"FRV1",1130580001.101,"42,7",7)
1964MU NQF0041 FLU RS
1965"FRV1",1130580001.101,"42,7",7,"F")
1966;PXRM(810.4,
1967"FRV1",1130580001.101,"42,7",8)
1968MU NQF0041 FLU DENOM RS
1969"FRV1",1130580001.101,"42,7",8,"F")
1970;PXRM(810.4,
1971"FRV1",1130580001.101,"43,7",7)
1972MU NQF0024 BMI 2-17YR NUM RS
1973"FRV1",1130580001.101,"43,7",7,"F")
1974;PXRM(810.4,
1975"FRV1",1130580001.101,"43,7",8)
1976MU NQF0024 BMI 2-17YRS DEM RS
1977"FRV1",1130580001.101,"43,7",8,"F")
1978;PXRM(810.4,
1979"FRV1",1130580001.101,"45,7",7)
1980MU NQF0059 HBA1C NUM RS
1981"FRV1",1130580001.101,"45,7",7,"F")
1982;PXRM(810.4,
1983"FRV1",1130580001.101,"45,7",8)
1984MU NQF0059 DM DENOM-ALL RS
1985"FRV1",1130580001.101,"45,7",8,"F")
1986;PXRM(810.4,
1987"FRV1",1130580001.101,"46,7",7)
1988MU NQF0064 NUM LDL RS
1989"FRV1",1130580001.101,"46,7",7,"F")
1990;PXRM(810.4,
1991"FRV1",1130580001.101,"46,7",8)
1992MU NQF0059 DM DENOM-ALL RS
1993"FRV1",1130580001.101,"46,7",8,"F")
1994;PXRM(810.4,
1995"FRV1",1130580001.101,"47,7",7)
1996MU NQF0061 NUM DM BP<140/90 RS
1997"FRV1",1130580001.101,"47,7",7,"F")
1998;PXRM(810.4,
1999"FRV1",1130580001.101,"47,7",8)
2000MU NQF0059 DM DENOM-ALL RS
2001"FRV1",1130580001.101,"47,7",8,"F")
2002;PXRM(810.4,
2003"FRV1",1130580001.101,"81,7",7)
2004MU NQF0028B TOBACCO INTERV NUM2 RS
2005"FRV1",1130580001.101,"81,7",7,"F")
2006;PXRM(810.4,
2007"FRV1",1130580001.101,"81,7",8)
2008MU NQF0028B TOBACCO INTERV DENOM RS
2009"FRV1",1130580001.101,"81,7",8,"F")
2010;PXRM(810.4,
2011"FRV1",1130580001.101,"82,7",7)
2012MU NQF0024 BMI PERCENTILE 2-10Y RS
2013"FRV1",1130580001.101,"82,7",7,"F")
2014;PXRM(810.4,
2015"FRV1",1130580001.101,"82,7",8)
2016MU NQF0024 BMI 2-10Y DENOM RS
2017"FRV1",1130580001.101,"82,7",8,"F")
2018;PXRM(810.4,
2019"FRV1",1130580001.101,"83,7",7)
2020MU NQF0038 NUM1 DPT RS
2021"FRV1",1130580001.101,"83,7",7,"F")
2022;PXRM(810.4,
2023"FRV1",1130580001.101,"83,7",8)
2024MU NQF0038 DENOM RS
2025"FRV1",1130580001.101,"83,7",8,"F")
2026;PXRM(810.4,
2027"FRV1",1130580001.101,"83,7",9)
2028MU NQF0038 CHILDREN'S IMMUNIZATIONS
2029"FRV1",1130580001.101,"83,7",9,"F")
2030;PXRM(810.2,
2031"FRV1",1130580001.101,"84,7",7)
2032MU NQF0038 NUM2 IPV RS
2033"FRV1",1130580001.101,"84,7",7,"F")
2034;PXRM(810.4,
2035"FRV1",1130580001.101,"84,7",8)
2036MU NQF0038 DENOM RS
2037"FRV1",1130580001.101,"84,7",8,"F")
2038;PXRM(810.4,
2039"FRV1",1130580001.101,"84,7",9)
2040MU NQF0038 CHILDREN'S IMMUNIZATIONS
2041"FRV1",1130580001.101,"84,7",9,"F")
2042;PXRM(810.2,
2043"FRV1",1130580001.101,"85,7",7)
2044MU NQF0038 NUM3-ALL RS
2045"FRV1",1130580001.101,"85,7",7,"F")
2046;PXRM(810.4,
2047"FRV1",1130580001.101,"85,7",8)
2048MU NQF0038 DENOM RS
2049"FRV1",1130580001.101,"85,7",8,"F")
2050;PXRM(810.4,
2051"FRV1",1130580001.101,"85,7",9)
2052MU NQF0038 CHILDREN'S IMMUNIZATIONS
2053"FRV1",1130580001.101,"85,7",9,"F")
2054;PXRM(810.2,
2055"FRV1",1130580001.101,"86,7",7)
2056MU NQF0038 NUM4 HIB RS
2057"FRV1",1130580001.101,"86,7",7,"F")
2058;PXRM(810.4,
2059"FRV1",1130580001.101,"86,7",8)
2060MU NQF0038 DENOM RS
2061"FRV1",1130580001.101,"86,7",8,"F")
2062;PXRM(810.4,
2063"FRV1",1130580001.101,"86,7",9)
2064MU NQF0038 CHILDREN'S IMMUNIZATIONS
2065"FRV1",1130580001.101,"86,7",9,"F")
2066;PXRM(810.2,
2067"FRV1",1130580001.101,"87,7",7)
2068MU NQF0038 NUM5 RS
2069"FRV1",1130580001.101,"87,7",7,"F")
2070;PXRM(810.4,
2071"FRV1",1130580001.101,"87,7",8)
2072MU NQF0038 DENOM RS
2073"FRV1",1130580001.101,"87,7",8,"F")
2074;PXRM(810.4,
2075"FRV1",1130580001.101,"87,7",9)
2076MU NQF0038 CHILDREN'S IMMUNIZATIONS
2077"FRV1",1130580001.101,"87,7",9,"F")
2078;PXRM(810.2,
2079"FRV1",1130580001.101,"88,7",7)
2080MU NQF0038 NUM6 VZV RS
2081"FRV1",1130580001.101,"88,7",7,"F")
2082;PXRM(810.4,
2083"FRV1",1130580001.101,"88,7",8)
2084MU NQF0038 DENOM RS
2085"FRV1",1130580001.101,"88,7",8,"F")
2086;PXRM(810.4,
2087"FRV1",1130580001.101,"88,7",9)
2088MU NQF0038 CHILDREN'S IMMUNIZATIONS
2089"FRV1",1130580001.101,"88,7",9,"F")
2090;PXRM(810.2,
2091"FRV1",1130580001.101,"89,7",7)
2092MU NQF0038 NUM7 PCV RS
2093"FRV1",1130580001.101,"89,7",7,"F")
2094;PXRM(810.4,
2095"FRV1",1130580001.101,"89,7",8)
2096MU NQF0038 DENOM RS
2097"FRV1",1130580001.101,"89,7",8,"F")
2098;PXRM(810.4,
2099"FRV1",1130580001.101,"89,7",9)
2100MU NQF0038 CHILDREN'S IMMUNIZATIONS
2101"FRV1",1130580001.101,"89,7",9,"F")
2102;PXRM(810.2,
2103"FRV1",1130580001.101,"90,7",7)
2104MU NQF0038 NUM8 HEP A RS
2105"FRV1",1130580001.101,"90,7",7,"F")
2106;PXRM(810.4,
2107"FRV1",1130580001.101,"90,7",8)
2108MU NQF0038 DENOM RS
2109"FRV1",1130580001.101,"90,7",8,"F")
2110;PXRM(810.4,
2111"FRV1",1130580001.101,"90,7",9)
2112MU NQF0038 CHILDREN'S IMMUNIZATIONS
2113"FRV1",1130580001.101,"90,7",9,"F")
2114;PXRM(810.2,
2115"FRV1",1130580001.101,"91,7",7)
2116MU NQF0038 NUM9 RV RS
2117"FRV1",1130580001.101,"91,7",7,"F")
2118;PXRM(810.4,
2119"FRV1",1130580001.101,"91,7",8)
2120MU NQF0038 DENOM RS
2121"FRV1",1130580001.101,"91,7",8,"F")
2122;PXRM(810.4,
2123"FRV1",1130580001.101,"91,7",9)
2124MU NQF0038 CHILDREN'S IMMUNIZATIONS
2125"FRV1",1130580001.101,"91,7",9,"F")
2126;PXRM(810.2,
2127"FRV1",1130580001.101,"92,7",7)
2128MU NQF0038 NUM10 INFLUENZA RS
2129"FRV1",1130580001.101,"92,7",7,"F")
2130;PXRM(810.4,
2131"FRV1",1130580001.101,"92,7",8)
2132MU NQF0038 DENOM RS
2133"FRV1",1130580001.101,"92,7",8,"F")
2134;PXRM(810.4,
2135"FRV1",1130580001.101,"92,7",9)
2136MU NQF0038 CHILDREN'S IMMUNIZATIONS
2137"FRV1",1130580001.101,"92,7",9,"F")
2138;PXRM(810.2,
2139"FRV1",1130580001.101,"93,7",7)
2140MU NQF0038 NUM11 COMBO5 RS
2141"FRV1",1130580001.101,"93,7",7,"F")
2142;PXRM(810.4,
2143"FRV1",1130580001.101,"93,7",8)
2144MU NQF0038 DENOM RS
2145"FRV1",1130580001.101,"93,7",8,"F")
2146;PXRM(810.4,
2147"FRV1",1130580001.101,"93,7",9)
2148MU NQF0038 CHILDREN'S IMMUNIZATIONS
2149"FRV1",1130580001.101,"93,7",9,"F")
2150;PXRM(810.2,
2151"FRV1",1130580001.101,"94,7",7)
2152MU NQF0038 NUM12 COMBO6 RS
2153"FRV1",1130580001.101,"94,7",7,"F")
2154;PXRM(810.4,
2155"FRV1",1130580001.101,"94,7",8)
2156MU NQF0038 DENOM RS
2157"FRV1",1130580001.101,"94,7",8,"F")
2158;PXRM(810.4,
2159"FRV1",1130580001.101,"94,7",9)
2160MU NQF0038 CHILDREN'S IMMUNIZATIONS
2161"FRV1",1130580001.101,"94,7",9,"F")
2162;PXRM(810.2,
2163"FRV1K",1130580001.101,"104,7",7)
2164B
2165"FRV1K",1130580001.101,"104,7",7,1)
2166MU NQF0024 BMI PERCENTILE 11-17Y RS
2167"FRV1K",1130580001.101,"104,7",8)
2168B
2169"FRV1K",1130580001.101,"104,7",8,1)
2170MU NQF0024 BMI 11-17Y DENOM RS
2171"FRV1K",1130580001.101,"23,7",7)
2172B
2173"FRV1K",1130580001.101,"23,7",7,1)
2174MU ED-1 NUMER RS
2175"FRV1K",1130580001.101,"23,7",8)
2176B
2177"FRV1K",1130580001.101,"23,7",8,1)
2178MU ED-1 DENOM RS
2179"FRV1K",1130580001.101,"24,7",7)
2180B
2181"FRV1K",1130580001.101,"24,7",7,1)
2182MU ED-2 NUMER RS
2183"FRV1K",1130580001.101,"24,7",8)
2184B
2185"FRV1K",1130580001.101,"24,7",8,1)
2186MU ED-2 DENOM RS
2187"FRV1K",1130580001.101,"25,7",7)
2188B
2189"FRV1K",1130580001.101,"25,7",7,1)
2190MU STK-2 NUMER RS
2191"FRV1K",1130580001.101,"25,7",8)
2192B
2193"FRV1K",1130580001.101,"25,7",8,1)
2194MU STK-2 DENOM RS
2195"FRV1K",1130580001.101,"26,7",7)
2196B
2197"FRV1K",1130580001.101,"26,7",7,1)
2198MU STK-3 NUMER RS
2199"FRV1K",1130580001.101,"26,7",8)
2200B
2201"FRV1K",1130580001.101,"26,7",8,1)
2202MU STK-3 DENOM RS
2203"FRV1K",1130580001.101,"27,7",7)
2204B
2205"FRV1K",1130580001.101,"27,7",7,1)
2206MU STK-4 NUMER RS
2207"FRV1K",1130580001.101,"27,7",8)
2208B
2209"FRV1K",1130580001.101,"27,7",8,1)
2210MU STK-4 DENOM RS
2211"FRV1K",1130580001.101,"28,7",7)
2212B
2213"FRV1K",1130580001.101,"28,7",7,1)
2214MU STK-5 NUMER RS
2215"FRV1K",1130580001.101,"28,7",8)
2216B
2217"FRV1K",1130580001.101,"28,7",8,1)
2218MU STK-5 DENOM RS
2219"FRV1K",1130580001.101,"29,7",7)
2220B
2221"FRV1K",1130580001.101,"29,7",7,1)
2222MU STK-6 NUMER RS
2223"FRV1K",1130580001.101,"29,7",8)
2224B
2225"FRV1K",1130580001.101,"29,7",8,1)
2226MU STK-6 DENOM RS
2227"FRV1K",1130580001.101,"30,7",7)
2228B
2229"FRV1K",1130580001.101,"30,7",7,1)
2230MU STK-8 NUMER RS
2231"FRV1K",1130580001.101,"30,7",8)
2232B
2233"FRV1K",1130580001.101,"30,7",8,1)
2234MU STK-8 DENOM RS
2235"FRV1K",1130580001.101,"31,7",7)
2236B
2237"FRV1K",1130580001.101,"31,7",7,1)
2238MU STK-10 NUMER RS
2239"FRV1K",1130580001.101,"31,7",8)
2240B
2241"FRV1K",1130580001.101,"31,7",8,1)
2242MU STK-10 DENOM RS
2243"FRV1K",1130580001.101,"32,7",7)
2244B
2245"FRV1K",1130580001.101,"32,7",7,1)
2246MU VTE-1 NUMER RS
2247"FRV1K",1130580001.101,"32,7",8)
2248B
2249"FRV1K",1130580001.101,"32,7",8,1)
2250MU VTE-1 DENOM RS
2251"FRV1K",1130580001.101,"33,7",7)
2252B
2253"FRV1K",1130580001.101,"33,7",7,1)
2254MU VTE-2 NUMER RS
2255"FRV1K",1130580001.101,"33,7",8)
2256B
2257"FRV1K",1130580001.101,"33,7",8,1)
2258MU VTE-2 DENOM RS
2259"FRV1K",1130580001.101,"34,7",7)
2260B
2261"FRV1K",1130580001.101,"34,7",7,1)
2262MU VTE-3 NUMER RS
2263"FRV1K",1130580001.101,"34,7",8)
2264B
2265"FRV1K",1130580001.101,"34,7",8,1)
2266MU VTE-3 DENOM RS
2267"FRV1K",1130580001.101,"35,7",7)
2268B
2269"FRV1K",1130580001.101,"35,7",7,1)
2270MU VTE-4 NUMER RS
2271"FRV1K",1130580001.101,"35,7",8)
2272B
2273"FRV1K",1130580001.101,"35,7",8,1)
2274MU VTE-4 DENOM RS
2275"FRV1K",1130580001.101,"36,7",7)
2276B
2277"FRV1K",1130580001.101,"36,7",7,1)
2278MU VTE-5 NUMER RS
2279"FRV1K",1130580001.101,"36,7",8)
2280B
2281"FRV1K",1130580001.101,"36,7",8,1)
2282MU VTE-5 DENOM RS
2283"FRV1K",1130580001.101,"37,7",7)
2284B
2285"FRV1K",1130580001.101,"37,7",7,1)
2286MU VTE-6 NUMER RS
2287"FRV1K",1130580001.101,"37,7",8)
2288B
2289"FRV1K",1130580001.101,"37,7",8,1)
2290MU VTE-6 DENOM RS
2291"FRV1K",1130580001.101,"39,7",7)
2292B
2293"FRV1K",1130580001.101,"39,7",7,1)
2294MU NQF0421 BMI NUM ALL RS
2295"FRV1K",1130580001.101,"39,7",8)
2296B
2297"FRV1K",1130580001.101,"39,7",8,1)
2298MU NQF0421 BMI DENOM ALL RS
2299"FRV1K",1130580001.101,"39,7",9)
2300B
2301"FRV1K",1130580001.101,"39,7",9,1)
2302MU NQF0421 ADULT BMI
2303"FRV1K",1130580001.101,"40,7",7)
2304B
2305"FRV1K",1130580001.101,"40,7",7,1)
2306MU NQF0013 HTN NUMER2 RS
2307"FRV1K",1130580001.101,"40,7",8)
2308B
2309"FRV1K",1130580001.101,"40,7",8,1)
2310MU NQF0013 HTN DENOM2 RS
2311"FRV1K",1130580001.101,"41,7",7)
2312B
2313"FRV1K",1130580001.101,"41,7",7,1)
2314MU NQF0028A TOBACCO SCREEN NUM RS
2315"FRV1K",1130580001.101,"41,7",8)
2316B
2317"FRV1K",1130580001.101,"41,7",8,1)
2318MU NQF0028B TOBACCO INTERV DENOM RS
2319"FRV1K",1130580001.101,"42,7",7)
2320B
2321"FRV1K",1130580001.101,"42,7",7,1)
2322MU NQF0041 FLU RS
2323"FRV1K",1130580001.101,"42,7",8)
2324B
2325"FRV1K",1130580001.101,"42,7",8,1)
2326MU NQF0041 FLU DENOM RS
2327"FRV1K",1130580001.101,"43,7",7)
2328B
2329"FRV1K",1130580001.101,"43,7",7,1)
2330MU NQF0024 BMI 2-17YR NUM RS
2331"FRV1K",1130580001.101,"43,7",8)
2332B
2333"FRV1K",1130580001.101,"43,7",8,1)
2334MU NQF0024 BMI 2-17YRS DEM RS
2335"FRV1K",1130580001.101,"45,7",7)
2336B
2337"FRV1K",1130580001.101,"45,7",7,1)
2338MU NQF0059 HBA1C NUM RS
2339"FRV1K",1130580001.101,"45,7",8)
2340B
2341"FRV1K",1130580001.101,"45,7",8,1)
2342MU NQF0059 DM DENOM-ALL RS
2343"FRV1K",1130580001.101,"46,7",7)
2344B
2345"FRV1K",1130580001.101,"46,7",7,1)
2346MU NQF0064 NUM LDL RS
2347"FRV1K",1130580001.101,"46,7",8)
2348B
2349"FRV1K",1130580001.101,"46,7",8,1)
2350MU NQF0059 DM DENOM-ALL RS
2351"FRV1K",1130580001.101,"47,7",7)
2352B
2353"FRV1K",1130580001.101,"47,7",7,1)
2354MU NQF0061 NUM DM BP<140/90 RS
2355"FRV1K",1130580001.101,"47,7",8)
2356B
2357"FRV1K",1130580001.101,"47,7",8,1)
2358MU NQF0059 DM DENOM-ALL RS
2359"FRV1K",1130580001.101,"81,7",7)
2360B
2361"FRV1K",1130580001.101,"81,7",7,1)
2362MU NQF0028B TOBACCO INTERV NUM2 RS
2363"FRV1K",1130580001.101,"81,7",8)
2364B
2365"FRV1K",1130580001.101,"81,7",8,1)
2366MU NQF0028B TOBACCO INTERV DENOM RS
2367"FRV1K",1130580001.101,"82,7",7)
2368B
2369"FRV1K",1130580001.101,"82,7",7,1)
2370MU NQF0024 BMI PERCENTILE 2-10Y RS
2371"FRV1K",1130580001.101,"82,7",8)
2372B
2373"FRV1K",1130580001.101,"82,7",8,1)
2374MU NQF0024 BMI 2-10Y DENOM RS
2375"FRV1K",1130580001.101,"83,7",7)
2376B
2377"FRV1K",1130580001.101,"83,7",7,1)
2378MU NQF0038 NUM1 DPT RS
2379"FRV1K",1130580001.101,"83,7",8)
2380B
2381"FRV1K",1130580001.101,"83,7",8,1)
2382MU NQF0038 DENOM RS
2383"FRV1K",1130580001.101,"83,7",9)
2384B
2385"FRV1K",1130580001.101,"83,7",9,1)
2386MU NQF0038 CHILDREN'S IMMUNIZATIONS
2387"FRV1K",1130580001.101,"84,7",7)
2388B
2389"FRV1K",1130580001.101,"84,7",7,1)
2390MU NQF0038 NUM2 IPV RS
2391"FRV1K",1130580001.101,"84,7",8)
2392B
2393"FRV1K",1130580001.101,"84,7",8,1)
2394MU NQF0038 DENOM RS
2395"FRV1K",1130580001.101,"84,7",9)
2396B
2397"FRV1K",1130580001.101,"84,7",9,1)
2398MU NQF0038 CHILDREN'S IMMUNIZATIONS
2399"FRV1K",1130580001.101,"85,7",7)
2400B
2401"FRV1K",1130580001.101,"85,7",7,1)
2402MU NQF0038 NUM3-ALL RS
2403"FRV1K",1130580001.101,"85,7",8)
2404B
2405"FRV1K",1130580001.101,"85,7",8,1)
2406MU NQF0038 DENOM RS
2407"FRV1K",1130580001.101,"85,7",9)
2408B
2409"FRV1K",1130580001.101,"85,7",9,1)
2410MU NQF0038 CHILDREN'S IMMUNIZATIONS
2411"FRV1K",1130580001.101,"86,7",7)
2412B
2413"FRV1K",1130580001.101,"86,7",7,1)
2414MU NQF0038 NUM4 HIB RS
2415"FRV1K",1130580001.101,"86,7",8)
2416B
2417"FRV1K",1130580001.101,"86,7",8,1)
2418MU NQF0038 DENOM RS
2419"FRV1K",1130580001.101,"86,7",9)
2420B
2421"FRV1K",1130580001.101,"86,7",9,1)
2422MU NQF0038 CHILDREN'S IMMUNIZATIONS
2423"FRV1K",1130580001.101,"87,7",7)
2424B
2425"FRV1K",1130580001.101,"87,7",7,1)
2426MU NQF0038 NUM5 RS
2427"FRV1K",1130580001.101,"87,7",8)
2428B
2429"FRV1K",1130580001.101,"87,7",8,1)
2430MU NQF0038 DENOM RS
2431"FRV1K",1130580001.101,"87,7",9)
2432B
2433"FRV1K",1130580001.101,"87,7",9,1)
2434MU NQF0038 CHILDREN'S IMMUNIZATIONS
2435"FRV1K",1130580001.101,"88,7",7)
2436B
2437"FRV1K",1130580001.101,"88,7",7,1)
2438MU NQF0038 NUM6 VZV RS
2439"FRV1K",1130580001.101,"88,7",8)
2440B
2441"FRV1K",1130580001.101,"88,7",8,1)
2442MU NQF0038 DENOM RS
2443"FRV1K",1130580001.101,"88,7",9)
2444B
2445"FRV1K",1130580001.101,"88,7",9,1)
2446MU NQF0038 CHILDREN'S IMMUNIZATIONS
2447"FRV1K",1130580001.101,"89,7",7)
2448B
2449"FRV1K",1130580001.101,"89,7",7,1)
2450MU NQF0038 NUM7 PCV RS
2451"FRV1K",1130580001.101,"89,7",8)
2452B
2453"FRV1K",1130580001.101,"89,7",8,1)
2454MU NQF0038 DENOM RS
2455"FRV1K",1130580001.101,"89,7",9)
2456B
2457"FRV1K",1130580001.101,"89,7",9,1)
2458MU NQF0038 CHILDREN'S IMMUNIZATIONS
2459"FRV1K",1130580001.101,"90,7",7)
2460B
2461"FRV1K",1130580001.101,"90,7",7,1)
2462MU NQF0038 NUM8 HEP A RS
2463"FRV1K",1130580001.101,"90,7",8)
2464B
2465"FRV1K",1130580001.101,"90,7",8,1)
2466MU NQF0038 DENOM RS
2467"FRV1K",1130580001.101,"90,7",9)
2468B
2469"FRV1K",1130580001.101,"90,7",9,1)
2470MU NQF0038 CHILDREN'S IMMUNIZATIONS
2471"FRV1K",1130580001.101,"91,7",7)
2472B
2473"FRV1K",1130580001.101,"91,7",7,1)
2474MU NQF0038 NUM9 RV RS
2475"FRV1K",1130580001.101,"91,7",8)
2476B
2477"FRV1K",1130580001.101,"91,7",8,1)
2478MU NQF0038 DENOM RS
2479"FRV1K",1130580001.101,"91,7",9)
2480B
2481"FRV1K",1130580001.101,"91,7",9,1)
2482MU NQF0038 CHILDREN'S IMMUNIZATIONS
2483"FRV1K",1130580001.101,"92,7",7)
2484B
2485"FRV1K",1130580001.101,"92,7",7,1)
2486MU NQF0038 NUM10 INFLUENZA RS
2487"FRV1K",1130580001.101,"92,7",8)
2488B
2489"FRV1K",1130580001.101,"92,7",8,1)
2490MU NQF0038 DENOM RS
2491"FRV1K",1130580001.101,"92,7",9)
2492B
2493"FRV1K",1130580001.101,"92,7",9,1)
2494MU NQF0038 CHILDREN'S IMMUNIZATIONS
2495"FRV1K",1130580001.101,"93,7",7)
2496B
2497"FRV1K",1130580001.101,"93,7",7,1)
2498MU NQF0038 NUM11 COMBO5 RS
2499"FRV1K",1130580001.101,"93,7",8)
2500B
2501"FRV1K",1130580001.101,"93,7",8,1)
2502MU NQF0038 DENOM RS
2503"FRV1K",1130580001.101,"93,7",9)
2504B
2505"FRV1K",1130580001.101,"93,7",9,1)
2506MU NQF0038 CHILDREN'S IMMUNIZATIONS
2507"FRV1K",1130580001.101,"94,7",7)
2508B
2509"FRV1K",1130580001.101,"94,7",7,1)
2510MU NQF0038 NUM12 COMBO6 RS
2511"FRV1K",1130580001.101,"94,7",8)
2512B
2513"FRV1K",1130580001.101,"94,7",8,1)
2514MU NQF0038 DENOM RS
2515"FRV1K",1130580001.101,"94,7",9)
2516B
2517"FRV1K",1130580001.101,"94,7",9,1)
2518MU NQF0038 CHILDREN'S IMMUNIZATIONS
2519"IX",1130580001.101,1130580001.101,"B",0)
25201130580001.101^B^New-Style B Index. Will be used as part of the key.^R^^F^IR^I^1130580001.101^^^^^LS
2521"IX",1130580001.101,1130580001.101,"B",1)
2522S ^C0Q(101,"B",$E(X,1,30),DA)=""
2523"IX",1130580001.101,1130580001.101,"B",2)
2524K ^C0Q(101,"B",$E(X,1,30),DA)
2525"IX",1130580001.101,1130580001.101,"B",2.5)
2526K ^C0Q(101,"B")
2527"IX",1130580001.101,1130580001.101,"B",11.1,0)
2528^.114IA^1^1
2529"IX",1130580001.101,1130580001.101,"B",11.1,1,0)
25301^F^1130580001.101^.01^30^1^F
2531"IX",1130580001.101,1130580001.101,"MU",0)
25321130580001.101^MU^MEANINGFUL USE YEAR KEY^R^^F^IR^I^1130580001.101^^^^^LS
2533"IX",1130580001.101,1130580001.101,"MU",1)
2534S ^C0Q(101,"MU",$E(X,1,30),DA)=""
2535"IX",1130580001.101,1130580001.101,"MU",2)
2536K ^C0Q(101,"MU",$E(X,1,30),DA)
2537"IX",1130580001.101,1130580001.101,"MU",2.5)
2538K ^C0Q(101,"MU")
2539"IX",1130580001.101,1130580001.101,"MU",11.1,0)
2540^.114IA^1^1
2541"IX",1130580001.101,1130580001.101,"MU",11.1,1,0)
25421^F^1130580001.101^.3^30^1^F
2543"KEY",1130580001.101,1130580001.101,"A",0)
25441130580001.101^A^P^562
2545"KEY",1130580001.101,1130580001.101,"A",2,0)
2546^.312IA^1^1
2547"KEY",1130580001.101,1130580001.101,"A",2,1,0)
2548.01^1130580001.101^1
2549"KEYPTR",1130580001.101,1130580001.101,"A")
25501130580001.101^B
2551"MBREQ")
25520
2553"PGL",1130580001.101,0,2,1)
2554NUMERATOR PATIENT LIST^P810.5'^PXRMXP(810.5,^0;2^Q
2555"PGL",1130580001.101,0,3,2)
2556DENOMINATOR PATIENT LIST^P810.5'^PXRMXP(810.5,^0;3^Q
2557"PGL",1130580001.101,7,2,1.1)
2558ALTERNATIVE NUMERATOR LIST^P1130580001.301'^C0Q(301,^7;2^Q
2559"PGL",1130580001.101,7,3,2.1)
2560ALTERNATIVE DENOMINATOR LIST^P1130580001.301'^C0Q(301,^7;3^Q
2561"PGL",1130580001.101,7,4,1.5)
2562NEGATIVE NUMERATOR LIST^P810.5'^PXRMXP(810.5,^7;4^Q
2563"PGL",1130580001.101,7,5,1.51)
2564ALTERNATE NEGATIVE NUM LIST^P1130580001.301'^C0Q(301,^7;5^Q
2565"PGL",1130580001.101,7,7,1.2)
2566NUMERATOR RULE SET^*P810.4'^PXRM(810.4,^7;7^S DIC("S")="I $P(^(0),U,3)=3" D ^DIC K DIC S DIC=$G(DIE),X=+Y K:Y<0 X
2567"PGL",1130580001.101,7,8,2.2)
2568DENOMINATOR RULE SET^*P810.4'^PXRM(810.4,^7;8^S DIC("S")="I $P(^(0),U,3)=3" D ^DIC K DIC S DIC=$G(DIE),X=+Y K:Y<0 X
2569"PGL",1130580001.101,7,9,2.5)
2570EXTRACT DEFINITION^P810.2'^PXRM(810.2,^7;9^Q
2571"PKG",215,-1)
25721^1
2573"PKG",215,0)
2574QUALITY MEASURES^C0Q^Tracks and Prints Quality Measures
2575"PKG",215,20,0)
2576^9.402P^^
2577"PKG",215,22,0)
2578^9.49I^1^1
2579"PKG",215,22,1,0)
25801.0^3120731^3120806^8
2581"PKG",215,22,1,"PAH",1,0)
25823^3120806^8
2583"PKG",215,22,1,"PAH",1,1,0)
2584^^155^155^3120806
2585"PKG",215,22,1,"PAH",1,1,1,0)
2586 Summary
2587"PKG",215,22,1,"PAH",1,1,2,0)
2588 =======
2589"PKG",215,22,1,"PAH",1,1,3,0)
2590 This build contains the Quality Measures file (#1130580001.101) fully
2591"PKG",215,22,1,"PAH",1,1,4,0)
2592 populated with the Reminder Rule Sets and if applicable Reminder Extract
2593"PKG",215,22,1,"PAH",1,1,5,0)
2594 definitions for use with the Quality Measures package for reporting for
2595"PKG",215,22,1,"PAH",1,1,6,0)
2596 Meaningful use Stage I.
2597"PKG",215,22,1,"PAH",1,1,7,0)
2598
2599"PKG",215,22,1,"PAH",1,1,8,0)
2600 Source, Copyright, & Licensing:
2601"PKG",215,22,1,"PAH",1,1,9,0)
2602 ===============================
2603"PKG",215,22,1,"PAH",1,1,10,0)
2604 This patch to WorldVistA 2.0 was produced by Sam Habiel on a copy of Dew
2605"PKG",215,22,1,"PAH",1,1,11,0)
2606Drop and tested on a virgin instance of WV EHR 3-09 patched with PXRM 2.0
2607"PKG",215,22,1,"PAH",1,1,12,0)
2608patches 12 and 17. The build was produced in July 2012.
2609"PKG",215,22,1,"PAH",1,1,13,0)
2610 Copyright WorldVistA 2012.
2611"PKG",215,22,1,"PAH",1,1,14,0)
2612 Licensed under GPL version 2 or later. Find it here:
2613"PKG",215,22,1,"PAH",1,1,15,0)
2614http://www.gnu.org/licenses/gpl-2.0.html
2615"PKG",215,22,1,"PAH",1,1,16,0)
2616 Released through VISTA Forum.
2617"PKG",215,22,1,"PAH",1,1,17,0)
2618
2619"PKG",215,22,1,"PAH",1,1,18,0)
2620 Functionality:
2621"PKG",215,22,1,"PAH",1,1,19,0)
2622 ==============
2623"PKG",215,22,1,"PAH",1,1,20,0)
2624 This patch is a pure data patch. It only installs reference data in the
2625"PKG",215,22,1,"PAH",1,1,21,0)
2626C0Q QUALITY MEASURE file (#1130580001.101). It relies on Reminder Package
2627"PKG",215,22,1,"PAH",1,1,22,0)
2628data (specifically rule sets and extracts) sent in C0Q*1.0*2.
2629"PKG",215,22,1,"PAH",1,1,23,0)
2630
2631"PKG",215,22,1,"PAH",1,1,24,0)
2632 Package Elements:
2633"PKG",215,22,1,"PAH",1,1,25,0)
2634 =================
2635"PKG",215,22,1,"PAH",1,1,26,0)
2636 This build transports entries in the C0Q QUALITY MEASURE file.
2637"PKG",215,22,1,"PAH",1,1,27,0)
2638
2639"PKG",215,22,1,"PAH",1,1,28,0)
2640 Routines:
2641"PKG",215,22,1,"PAH",1,1,29,0)
2642 =========
2643"PKG",215,22,1,"PAH",1,1,30,0)
2644 <None>
2645"PKG",215,22,1,"PAH",1,1,31,0)
2646
2647"PKG",215,22,1,"PAH",1,1,32,0)
2648 Documentation:
2649"PKG",215,22,1,"PAH",1,1,33,0)
2650 <None besides this KIDS description>
2651"PKG",215,22,1,"PAH",1,1,34,0)
2652
2653"PKG",215,22,1,"PAH",1,1,35,0)
2654 Test Sites:
2655"PKG",215,22,1,"PAH",1,1,36,0)
2656 ===========
2657"PKG",215,22,1,"PAH",1,1,37,0)
2658 <None>
2659"PKG",215,22,1,"PAH",1,1,38,0)
2660
2661"PKG",215,22,1,"PAH",1,1,39,0)
2662 Compliance:
2663"PKG",215,22,1,"PAH",1,1,40,0)
2664 ===========
2665"PKG",215,22,1,"PAH",1,1,41,0)
2666 This software complies with the VA MUMPS Programming Standards and
2667"PKG",215,22,1,"PAH",1,1,42,0)
2668 Conventions (version 3 April 2007).
2669"PKG",215,22,1,"PAH",1,1,43,0)
2670
2671"PKG",215,22,1,"PAH",1,1,44,0)
2672 Installation Instructions:
2673"PKG",215,22,1,"PAH",1,1,45,0)
2674 ==========================
2675"PKG",215,22,1,"PAH",1,1,46,0)
2676 Pre-installation:
2677"PKG",215,22,1,"PAH",1,1,47,0)
2678
2679"PKG",215,22,1,"PAH",1,1,48,0)
2680 Prerequisite patches: (both found on the trac server here:
2681"PKG",215,22,1,"PAH",1,1,49,0)
2682 https://trac.opensourcevista.net/svn/qrda/C0Q/trunk/kids/)
2683"PKG",215,22,1,"PAH",1,1,50,0)
2684 C0Q*1.0*2
2685"PKG",215,22,1,"PAH",1,1,51,0)
2686 QUALITY MEASURES 1.0
2687"PKG",215,22,1,"PAH",1,1,52,0)
2688
2689"PKG",215,22,1,"PAH",1,1,53,0)
2690 Users can remain on the system while this patch is installed.
2691"PKG",215,22,1,"PAH",1,1,54,0)
2692
2693"PKG",215,22,1,"PAH",1,1,55,0)
2694 Install Time - less than 1 minute.
2695"PKG",215,22,1,"PAH",1,1,56,0)
2696
2697"PKG",215,22,1,"PAH",1,1,57,0)
2698 1. LOAD TRANSPORT GLOBAL
2699"PKG",215,22,1,"PAH",1,1,58,0)
2700
2701"PKG",215,22,1,"PAH",1,1,59,0)
2702 Choose the PackMan message containing this patch and invoke the
2703"PKG",215,22,1,"PAH",1,1,60,0)
2704 INSTALL/CHECK MESSAGE PackMan option to unload the build, or
2705"PKG",215,22,1,"PAH",1,1,61,0)
2706 Use the Load a Distribution option in KIDS to load it from a
2707"PKG",215,22,1,"PAH",1,1,62,0)
2708 host file.
2709"PKG",215,22,1,"PAH",1,1,63,0)
2710
2711"PKG",215,22,1,"PAH",1,1,64,0)
2712 2. START UP KIDS
2713"PKG",215,22,1,"PAH",1,1,65,0)
2714
2715"PKG",215,22,1,"PAH",1,1,66,0)
2716 Start up the Kernel Installation and Distribution System Menu
2717"PKG",215,22,1,"PAH",1,1,67,0)
2718 [XPD MAIN]:
2719"PKG",215,22,1,"PAH",1,1,68,0)
2720
2721"PKG",215,22,1,"PAH",1,1,69,0)
2722 Edits and Distribution ...
2723"PKG",215,22,1,"PAH",1,1,70,0)
2724 Utilities ...
2725"PKG",215,22,1,"PAH",1,1,71,0)
2726 Installation ...
2727"PKG",215,22,1,"PAH",1,1,72,0)
2728
2729"PKG",215,22,1,"PAH",1,1,73,0)
2730 Select Kernel Installation & Distribution System Option: INStallation
2731"PKG",215,22,1,"PAH",1,1,74,0)
2732 ---
2733"PKG",215,22,1,"PAH",1,1,75,0)
2734 Load a Distribution
2735"PKG",215,22,1,"PAH",1,1,76,0)
2736 Print Transport Global
2737"PKG",215,22,1,"PAH",1,1,77,0)
2738 Compare Transport Global to Current System
2739"PKG",215,22,1,"PAH",1,1,78,0)
2740 Verify Checksums in Transport Global
2741"PKG",215,22,1,"PAH",1,1,79,0)
2742 Install Package(s)
2743"PKG",215,22,1,"PAH",1,1,80,0)
2744 Restart Install of Package(s)
2745"PKG",215,22,1,"PAH",1,1,81,0)
2746 Unload a Distribution
2747"PKG",215,22,1,"PAH",1,1,82,0)
2748 Backup a Transport Global
2749"PKG",215,22,1,"PAH",1,1,83,0)
2750
2751"PKG",215,22,1,"PAH",1,1,84,0)
2752 Select Installation Option:
2753"PKG",215,22,1,"PAH",1,1,85,0)
2754
2755"PKG",215,22,1,"PAH",1,1,86,0)
2756 3. Select Installation Option:
2757"PKG",215,22,1,"PAH",1,1,87,0)
2758
2759"PKG",215,22,1,"PAH",1,1,88,0)
2760 NOTE: The following are OPTIONAL - (When prompted for the INSTALL
2761"PKG",215,22,1,"PAH",1,1,89,0)
2762 NAME, enter C0Q*1.0*3):
2763"PKG",215,22,1,"PAH",1,1,90,0)
2764
2765"PKG",215,22,1,"PAH",1,1,91,0)
2766 a. Backup a Transport Global - This option will create a backup
2767"PKG",215,22,1,"PAH",1,1,92,0)
2768 message of any routines exported with this patch. It will not
2769"PKG",215,22,1,"PAH",1,1,93,0)
2770 backup any other changes such as DD's or templates.
2771"PKG",215,22,1,"PAH",1,1,94,0)
2772 b. Compare Transport Global to Current System - This option will
2773"PKG",215,22,1,"PAH",1,1,95,0)
2774 allow you to view all changes that will be made when this patch
2775"PKG",215,22,1,"PAH",1,1,96,0)
2776 is installed. It compares all components of this patch
2777"PKG",215,22,1,"PAH",1,1,97,0)
2778 (routines, DD's, templates, etc.).
2779"PKG",215,22,1,"PAH",1,1,98,0)
2780 c. Verify Checksums in Transport Global - This option will allow
2781"PKG",215,22,1,"PAH",1,1,99,0)
2782 you to ensure the integrity of the routines that are in the
2783"PKG",215,22,1,"PAH",1,1,100,0)
2784 transport global.
2785"PKG",215,22,1,"PAH",1,1,101,0)
2786
2787"PKG",215,22,1,"PAH",1,1,102,0)
2788 4. Select Installation Option: Install Package(s)
2789"PKG",215,22,1,"PAH",1,1,103,0)
2790
2791"PKG",215,22,1,"PAH",1,1,104,0)
2792 **This is the step to start the installation of this KIDS patch:
2793"PKG",215,22,1,"PAH",1,1,105,0)
2794
2795"PKG",215,22,1,"PAH",1,1,106,0)
2796 a. Choose the Install Package(s) option to start the patch install
2797"PKG",215,22,1,"PAH",1,1,107,0)
2798 and enter "C0Q*1.0*3" at the INSTALL NAME prompt.
2799"PKG",215,22,1,"PAH",1,1,108,0)
2800 b. When prompted 'Want KIDS to Rebuild Menu Trees Upon Completion of
2801"PKG",215,22,1,"PAH",1,1,109,0)
2802 Install? NO//' answer NO
2803"PKG",215,22,1,"PAH",1,1,110,0)
2804 c. When prompted 'Want KIDS to INHIBIT LOGONs during the install?
2805"PKG",215,22,1,"PAH",1,1,111,0)
2806 NO//' answer NO
2807"PKG",215,22,1,"PAH",1,1,112,0)
2808 d. When prompted 'Want to DISABLE Scheduled Options, Menu Options,
2809"PKG",215,22,1,"PAH",1,1,113,0)
2810 and Protocols? NO//' answer NO
2811"PKG",215,22,1,"PAH",1,1,114,0)
2812
2813"PKG",215,22,1,"PAH",1,1,115,0)
2814
2815"PKG",215,22,1,"PAH",1,1,116,0)
2816Here is an example installation log.
2817"PKG",215,22,1,"PAH",1,1,117,0)
2818Select INSTALL NAME: C0Q*1.0*3 Loaded from Distribution Loaded
2819"PKG",215,22,1,"PAH",1,1,118,0)
2820from Di
2821"PKG",215,22,1,"PAH",1,1,119,0)
2822stribution 8/3/12@16:32:30
2823"PKG",215,22,1,"PAH",1,1,120,0)
2824 => SDFGHJKL ;Created on Aug 03, 2012@16:31:28
2825"PKG",215,22,1,"PAH",1,1,121,0)
2826
2827"PKG",215,22,1,"PAH",1,1,122,0)
2828This Distribution was loaded on Aug 03, 2012@16:32:30 with header of
2829"PKG",215,22,1,"PAH",1,1,123,0)
2830 SDFGHJKL ;Created on Aug 03, 2012@16:31:28
2831"PKG",215,22,1,"PAH",1,1,124,0)
2832 It consisted of the following Install(s):
2833"PKG",215,22,1,"PAH",1,1,125,0)
2834 C0Q*1.0*3
2835"PKG",215,22,1,"PAH",1,1,126,0)
2836
2837"PKG",215,22,1,"PAH",1,1,127,0)
2838 Checking C0Q*1.0*3 for overlap with VOE 1.0 . OK
2839"PKG",215,22,1,"PAH",1,1,128,0)
2840 No overlap found
2841"PKG",215,22,1,"PAH",1,1,129,0)
2842DEVICE: HOME// PHOME HOME PRINTER
2843"PKG",215,22,1,"PAH",1,1,130,0)
2844
2845"PKG",215,22,1,"PAH",1,1,131,0)
2846
2847"PKG",215,22,1,"PAH",1,1,132,0)
2848 Install Started for C0Q*1.0*3 :
2849"PKG",215,22,1,"PAH",1,1,133,0)
2850 Aug 03, 2012@16:35:24
2851"PKG",215,22,1,"PAH",1,1,134,0)
2852
2853"PKG",215,22,1,"PAH",1,1,135,0)
2854Build Distribution Date: Aug 03, 2012
2855"PKG",215,22,1,"PAH",1,1,136,0)
2856
2857"PKG",215,22,1,"PAH",1,1,137,0)
2858 Installing Routines:.
2859"PKG",215,22,1,"PAH",1,1,138,0)
2860 Aug 03, 2012@16:35:24
2861"PKG",215,22,1,"PAH",1,1,139,0)
2862
2863"PKG",215,22,1,"PAH",1,1,140,0)
2864 Installing Data Dictionaries: ..
2865"PKG",215,22,1,"PAH",1,1,141,0)
2866 Aug 03, 2012@16:35:24
2867"PKG",215,22,1,"PAH",1,1,142,0)
2868
2869"PKG",215,22,1,"PAH",1,1,143,0)
2870 Installing Data:
2871"PKG",215,22,1,"PAH",1,1,144,0)
2872 Aug 03, 2012@16:35:24
2873"PKG",215,22,1,"PAH",1,1,145,0)
2874
2875"PKG",215,22,1,"PAH",1,1,146,0)
2876 Updating Routine file.....
2877"PKG",215,22,1,"PAH",1,1,147,0)
2878
2879"PKG",215,22,1,"PAH",1,1,148,0)
2880 Updating KIDS files.......
2881"PKG",215,22,1,"PAH",1,1,149,0)
2882
2883"PKG",215,22,1,"PAH",1,1,150,0)
2884 C0Q*1.0*3 Installed.
2885"PKG",215,22,1,"PAH",1,1,151,0)
2886 Aug 03, 2012@16:35:24
2887"PKG",215,22,1,"PAH",1,1,152,0)
2888
2889"PKG",215,22,1,"PAH",1,1,153,0)
2890 Not a VA primary domain
2891"PKG",215,22,1,"PAH",1,1,154,0)
2892
2893"PKG",215,22,1,"PAH",1,1,155,0)
2894 NO Install Message sent
2895"QUES","XPF1",0)
2896Y
2897"QUES","XPF1","??")
2898^D REP^XPDH
2899"QUES","XPF1","A")
2900Shall I write over your |FLAG| File
2901"QUES","XPF1","B")
2902YES
2903"QUES","XPF1","M")
2904D XPF1^XPDIQ
2905"QUES","XPF2",0)
2906Y
2907"QUES","XPF2","??")
2908^D DTA^XPDH
2909"QUES","XPF2","A")
2910Want my data |FLAG| yours
2911"QUES","XPF2","B")
2912YES
2913"QUES","XPF2","M")
2914D XPF2^XPDIQ
2915"QUES","XPI1",0)
2916YO
2917"QUES","XPI1","??")
2918^D INHIBIT^XPDH
2919"QUES","XPI1","A")
2920Want KIDS to INHIBIT LOGONs during the install
2921"QUES","XPI1","B")
2922NO
2923"QUES","XPI1","M")
2924D XPI1^XPDIQ
2925"QUES","XPM1",0)
2926PO^VA(200,:EM
2927"QUES","XPM1","??")
2928^D MG^XPDH
2929"QUES","XPM1","A")
2930Enter the Coordinator for Mail Group '|FLAG|'
2931"QUES","XPM1","B")
2932
2933"QUES","XPM1","M")
2934D XPM1^XPDIQ
2935"QUES","XPO1",0)
2936Y
2937"QUES","XPO1","??")
2938^D MENU^XPDH
2939"QUES","XPO1","A")
2940Want KIDS to Rebuild Menu Trees Upon Completion of Install
2941"QUES","XPO1","B")
2942NO
2943"QUES","XPO1","M")
2944D XPO1^XPDIQ
2945"QUES","XPZ1",0)
2946Y
2947"QUES","XPZ1","??")
2948^D OPT^XPDH
2949"QUES","XPZ1","A")
2950Want to DISABLE Scheduled Options, Menu Options, and Protocols
2951"QUES","XPZ1","B")
2952NO
2953"QUES","XPZ1","M")
2954D XPZ1^XPDIQ
2955"QUES","XPZ2",0)
2956Y
2957"QUES","XPZ2","??")
2958^D RTN^XPDH
2959"QUES","XPZ2","A")
2960Want to MOVE routines to other CPUs
2961"QUES","XPZ2","B")
2962NO
2963"QUES","XPZ2","M")
2964D XPZ2^XPDIQ
2965"SEC","^DD",1130580001.101,1130580001.101,3.1,9)
2966
2967"SEC","^DIC",1130580001.101,1130580001.101,0,"AUDIT")
2968@
2969"SEC","^DIC",1130580001.101,1130580001.101,0,"DD")
2970@
2971"SEC","^DIC",1130580001.101,1130580001.101,0,"DEL")
2972@
2973"SEC","^DIC",1130580001.101,1130580001.101,0,"LAYGO")
2974@
2975"SEC","^DIC",1130580001.101,1130580001.101,0,"RD")
2976@
2977"SEC","^DIC",1130580001.101,1130580001.101,0,"WR")
2978@
2979"VER")
29808.0^22.0
2981"^DD",1130580001.101,1130580001.101,0)
2982FIELD^^.3^18
2983"^DD",1130580001.101,1130580001.101,0,"DDA")
2984N
2985"^DD",1130580001.101,1130580001.101,0,"DT")
29863111201
2987"^DD",1130580001.101,1130580001.101,0,"ID",.7)
2988W:$D(^(5)) " ",$P(^(5),U,1)
2989"^DD",1130580001.101,1130580001.101,0,"IX","B",1130580001.101,.01)
2990
2991"^DD",1130580001.101,1130580001.101,0,"NM","C0Q QUALITY MEASURE")
2992
2993"^DD",1130580001.101,1130580001.101,0,"PT",1130580001.2011,.01)
2994
2995"^DD",1130580001.101,1130580001.101,0,"VRPK")
2996C0Q
2997"^DD",1130580001.101,1130580001.101,.01,0)
2998NAME^RF^^0;1^K:$L(X)>30!($L(X)<1)!'(X'?1P.E) X
2999"^DD",1130580001.101,1130580001.101,.01,.1)
3000MEASURE NAME
3001"^DD",1130580001.101,1130580001.101,.01,1,0)
3002^.1
3003"^DD",1130580001.101,1130580001.101,.01,1,1,0)
30041130580001.101^B
3005"^DD",1130580001.101,1130580001.101,.01,1,1,1)
3006S ^C0Q(101,"B",$E(X,1,30),DA)=""
3007"^DD",1130580001.101,1130580001.101,.01,1,1,2)
3008K ^C0Q(101,"B",$E(X,1,30),DA)
3009"^DD",1130580001.101,1130580001.101,.01,3)
3010Answer must be 1-30 characters in length
3011"^DD",1130580001.101,1130580001.101,.01,"DT")
30123101012
3013"^DD",1130580001.101,1130580001.101,.3,0)
3014MU YEAR KEY^F^^7;6^K:$L(X)>30!($L(X)<1) X
3015"^DD",1130580001.101,1130580001.101,.3,.1)
3016MEANINGFUL USE YEAR KEY
3017"^DD",1130580001.101,1130580001.101,.3,3)
3018Answer must be 1-30 characters in length.
3019"^DD",1130580001.101,1130580001.101,.3,"DT")
30203111201
3021"^DD",1130580001.101,1130580001.101,.5,0)
3022TITLE^F^^1;1^K:$L(X)>240!($L(X)<3) X
3023"^DD",1130580001.101,1130580001.101,.5,.1)
3024MEASURE TITLE
3025"^DD",1130580001.101,1130580001.101,.5,3)
3026Answer must be 3-240 characters in length
3027"^DD",1130580001.101,1130580001.101,.5,"DT")
30283110430
3029"^DD",1130580001.101,1130580001.101,.61,0)
3030VERY LONG DESCRIPTION^1130580001.111^^6;0
3031"^DD",1130580001.101,1130580001.101,.7,0)
3032DISPLAY NAME^F^^5;1^K:$L(X)>240!($L(X)<3) X
3033"^DD",1130580001.101,1130580001.101,.7,.1)
3034QRDA DISPLAY NAME
3035"^DD",1130580001.101,1130580001.101,.7,3)
3036Answer must be 3-240 characters in length
3037"^DD",1130580001.101,1130580001.101,.7,"DT")
30383101012
3039"^DD",1130580001.101,1130580001.101,.8,0)
3040REPORTING NAME^F^^7;1^K:$L(X)>30!($L(X)<3) X
3041"^DD",1130580001.101,1130580001.101,.8,.1)
3042REPORTING MEASURE NAME
3043"^DD",1130580001.101,1130580001.101,.8,3)
3044Answer must be 3-30 characters in length
3045"^DD",1130580001.101,1130580001.101,.8,"DT")
30463110615
3047"^DD",1130580001.101,1130580001.101,1,0)
3048NUMERATOR PATIENT LIST^P810.5'^PXRMXP(810.5,^0;2^Q
3049"^DD",1130580001.101,1130580001.101,1,.1)
3050MEASURE NUMERATOR PATIENT LIST
3051"^DD",1130580001.101,1130580001.101,1,"DT")
30523101012
3053"^DD",1130580001.101,1130580001.101,1.1,0)
3054ALTERNATIVE NUMERATOR LIST^P1130580001.301'^C0Q(301,^7;2^Q
3055"^DD",1130580001.101,1130580001.101,1.1,"DT")
30563110805
3057"^DD",1130580001.101,1130580001.101,1.2,0)
3058NUMERATOR RULE SET^*P810.4'^PXRM(810.4,^7;7^S DIC("S")="I $P(^(0),U,3)=3" D ^DIC K DIC S DIC=$G(DIE),X=+Y K:Y<0 X
3059"^DD",1130580001.101,1130580001.101,1.2,3)
3060Enter the reminder rule set to use for this measure.
3061"^DD",1130580001.101,1130580001.101,1.2,12)
3062If the type of the reminder list rule is a Rule Set.
3063"^DD",1130580001.101,1130580001.101,1.2,12.1)
3064S DIC("S")="I $P(^(0),U,3)=3"
3065"^DD",1130580001.101,1130580001.101,1.2,21,0)
3066^^5^5^3120716^
3067"^DD",1130580001.101,1130580001.101,1.2,21,1,0)
3068This is the numerator reminder rule set to use for the quality measure.
3069"^DD",1130580001.101,1130580001.101,1.2,21,2,0)
3070
3071"^DD",1130580001.101,1130580001.101,1.2,21,3,0)
3072The rule set is used to generate a patient list, which this package
3073"^DD",1130580001.101,1130580001.101,1.2,21,4,0)
3074referneces. The contents of the patient list will produce the count for
3075"^DD",1130580001.101,1130580001.101,1.2,21,5,0)
3076the measure. This count is for the numerator.
3077"^DD",1130580001.101,1130580001.101,1.2,"DT")
30783120716
3079"^DD",1130580001.101,1130580001.101,1.5,0)
3080NEGATIVE NUMERATOR LIST^P810.5'^PXRMXP(810.5,^7;4^Q
3081"^DD",1130580001.101,1130580001.101,1.5,.1)
3082LIST OF PATIENTS THAT DO NOT MEET THE REQUIREMENTS
3083"^DD",1130580001.101,1130580001.101,1.5,"DT")
30843110809
3085"^DD",1130580001.101,1130580001.101,1.51,0)
3086ALTERNATE NEGATIVE NUM LIST^P1130580001.301'^C0Q(301,^7;5^Q
3087"^DD",1130580001.101,1130580001.101,1.51,.1)
3088NEGATIVE NUMERATOR LIST IN C0Q PATIENT LIST FILE
3089"^DD",1130580001.101,1130580001.101,1.51,"DT")
30903110809
3091"^DD",1130580001.101,1130580001.101,2,0)
3092DENOMINATOR PATIENT LIST^P810.5'^PXRMXP(810.5,^0;3^Q
3093"^DD",1130580001.101,1130580001.101,2,.1)
3094MEASURE DENOMINATOR PATIENT LIST
3095"^DD",1130580001.101,1130580001.101,2,"DT")
30963101012
3097"^DD",1130580001.101,1130580001.101,2.1,0)
3098ALTERNATIVE DENOMINATOR LIST^P1130580001.301'^C0Q(301,^7;3^Q
3099"^DD",1130580001.101,1130580001.101,2.1,"DT")
31003110805
3101"^DD",1130580001.101,1130580001.101,2.2,0)
3102DENOMINATOR RULE SET^*P810.4'^PXRM(810.4,^7;8^S DIC("S")="I $P(^(0),U,3)=3" D ^DIC K DIC S DIC=$G(DIE),X=+Y K:Y<0 X
3103"^DD",1130580001.101,1130580001.101,2.2,3)
3104Enter the reminder rule set to use for this measure.
3105"^DD",1130580001.101,1130580001.101,2.2,12)
3106If the type of the reminder list rule is a Rule Set.
3107"^DD",1130580001.101,1130580001.101,2.2,12.1)
3108S DIC("S")="I $P(^(0),U,3)=3"
3109"^DD",1130580001.101,1130580001.101,2.2,21,0)
3110^^5^5^3120716^
3111"^DD",1130580001.101,1130580001.101,2.2,21,1,0)
3112This is the denominator reminder rule set to use for the quality measure.
3113"^DD",1130580001.101,1130580001.101,2.2,21,2,0)
3114
3115"^DD",1130580001.101,1130580001.101,2.2,21,3,0)
3116The rule set is used to generate a patient list, which this package
3117"^DD",1130580001.101,1130580001.101,2.2,21,4,0)
3118referneces. The contents of the patient list will produce the count for
3119"^DD",1130580001.101,1130580001.101,2.2,21,5,0)
3120the measure. This count is for the denominator.
3121"^DD",1130580001.101,1130580001.101,2.2,"DT")
31223120716
3123"^DD",1130580001.101,1130580001.101,2.5,0)
3124EXTRACT DEFINITION^P810.2'^PXRM(810.2,^7;9^Q
3125"^DD",1130580001.101,1130580001.101,2.5,3)
3126Select a Reminder Extract Definition for this measure
3127"^DD",1130580001.101,1130580001.101,2.5,21,0)
3128^^4^4^3120726^
3129"^DD",1130580001.101,1130580001.101,2.5,21,1,0)
3130If this measure depends upon a reminder extract definition, you can add
3131"^DD",1130580001.101,1130580001.101,2.5,21,2,0)
3132this extract definition here. This will alter how the Quality Measures
3133"^DD",1130580001.101,1130580001.101,2.5,21,3,0)
3134package computes the measure to use the extract in addition and prior to
3135"^DD",1130580001.101,1130580001.101,2.5,21,4,0)
3136the rule sets.
3137"^DD",1130580001.101,1130580001.101,2.5,"DT")
31383120726
3139"^DD",1130580001.101,1130580001.101,3,0)
3140QRDA TEMPLATE ROOT^F^^0;4^K:$L(X)>120!($L(X)<3) X
3141"^DD",1130580001.101,1130580001.101,3,.1)
3142MEASURE TEMPLATE ROOT FOR QRDA DOCUMENT
3143"^DD",1130580001.101,1130580001.101,3,3)
3144Answer must be 3-120 characters in length
3145"^DD",1130580001.101,1130580001.101,3,"DT")
31463101012
3147"^DD",1130580001.101,1130580001.101,3.1,0)
3148QRDA MEASURE SYSTEM OID^CJ^^ ; ^S X="2.16.840.1.113883.3.249.12"
3149"^DD",1130580001.101,1130580001.101,3.1,.1)
3150QRDA SYSTEM OID (FIXED)
3151"^DD",1130580001.101,1130580001.101,3.1,9.01)
3152
3153"^DD",1130580001.101,1130580001.101,3.1,9.1)
3154S X="2.16.840.1.113883.3.249.12"
3155"^DD",1130580001.101,1130580001.101,3.1,"DT")
31563101012
3157"^DD",1130580001.101,1130580001.101,3.2,0)
3158QRDA CODE^F^^4;1^K:$L(X)>80!($L(X)<1) X
3159"^DD",1130580001.101,1130580001.101,3.2,.1)
3160QRDA MEASURE CODE
3161"^DD",1130580001.101,1130580001.101,3.2,3)
3162Answer must be 1-80 characters in length
3163"^DD",1130580001.101,1130580001.101,3.2,"DT")
31643101012
3165"^DD",1130580001.101,1130580001.111,0)
3166VERY LONG DESCRIPTION SUB-FIELD^^.01^1
3167"^DD",1130580001.101,1130580001.111,0,"DT")
31683101013
3169"^DD",1130580001.101,1130580001.111,0,"NM","VERY LONG DESCRIPTION")
3170
3171"^DD",1130580001.101,1130580001.111,0,"UP")
31721130580001.101
3173"^DD",1130580001.101,1130580001.111,.01,0)
3174VERY LONG DESCRIPTION^Wx^^0;1
3175"^DD",1130580001.101,1130580001.111,.01,.1)
3176LONGER DESCRIPTION - IF IT DOESN'T FIT IN .6
3177"^DD",1130580001.101,1130580001.111,.01,3)
3178LONGER DESCRIPTION - INSTEAD OF LONG DESCRIPTION
3179"^DD",1130580001.101,1130580001.111,.01,"DT")
31803101013
3181"^DIC",1130580001.101,1130580001.101,0)
3182C0Q QUALITY MEASURE^1130580001.101
3183"^DIC",1130580001.101,1130580001.101,0,"GL")
3184^C0Q(101,
3185"^DIC",1130580001.101,"B","C0Q QUALITY MEASURE",1130580001.101)
3186
3187**END**
3188**END**
Note: See TracBrowser for help on using the repository browser.